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INTRODUCTION 
Myocardial infarction 
Myocardial infarction (MI, heart attack, coronary thrombosis) occurs when a 
coronary vessel becomes occluded for more than 6 hours[1], it is the irreversible 
necrosis of heart muscles secondary to prolonged ischemia, usually results from an 
imbalance of oxygen supply and demand[2].             
It is one of the serious disorders among ischemic heart diseases invariably 
followed by several biochemical alterations such as hyperlipidemia, lipid peroxidation, 
free radical damage, thrombosis, etc., leading to qualitative and quantitative alteration 
of myocardium. The appearance of cardiac enzymes in the circulation generally 
indicates myocardial necrosis [3].   
 
Fig 1: Myocardial infarction in left coronary artery 
Prevalence rate of myocardial infarction  
Globally, cardiovascular diseases constitute a leading cause of mortality. The 
Incidence and prevalence of myocardial infarction progressively increased with age 
during the later half of the last century[2]. Developing countries like India are also 
struggling to manage the impact of cardiovascular diseases (CVD) along with the 
growing burden of obesity[4]. It may account for one third of the deaths by the year 
2020. Current projections suggest that India will have the largest CVD burden in the 
world by the year 2020[5]. 
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Clinical classification of myocardial infarction 
For the sake of immediate treatment strategies, such as reperfusion therapy, it 
is usual practice to designate MI in patients with chest discomfort, or other ischaemic 
symptoms that develop ST elevation in two contiguous leads, as an ‘ST elevation MI’ 
(STEMI). In contrast, patients without ST elevation at presentation are usually 
designated as having a ‘non-ST elevation MI’(NSTEMI). Many patients with MI 
develop Q waves (Q wave MI), but others do not (non-Q MI). Patients without elevated 
biomarker values can be diagnosed as having unstable angina. In addition to these 
categories, MI is classified into various types, based on pathological, clinical and 
prognostic differences, along with different treatment strategies[6]. 
Spontaneous myocardial infarction (M1type 1) 
This is an event related to atherosclerotic plaque rupture, ulceration, fissuring, 
erosion, or dissection with resulting intraluminal thrombus in one or more of the 
coronary arteries, leading to decreased myocardial blood flow or distal platelet emboli 
with ensuing myocyte necrosis. The patient may have underlying severe CAD but, on 
occasion (5 to 20%), non-obstructive or no CAD may be found at angiography, 
particularly in women[6]. 
Myocardial infarction secondary to an ischaemic imbalance (M1 type 2) 
In instances of myocardial injury with necrosis, where a condition other than 
CAD contributes to an imbalance between myocardial oxygen supply and/or demand, 
the term ‘MI type 2’ is employed (Figure 2). In critically ill patients, or in patients 
undergoing major (non-cardiac) surgery, elevated values of cardiac biomarkers may 
appear, due to the direct toxic effects of endogenous or exogenous high circulating 
catecholamine levels. Also, coronary vasospasm and/or endothelial dysfunction have 
the potential to cause MI[7]. 
Cardiac death due to myocardial infarction (M1 type 3) 
Patients who suffer cardiac death, with symptoms suggestive of myocardial 
ischaemia accompanied by presumed new ischaemic ECG changes or new LBBB but 
without available biomarker values represent a challenging diagnostic group. These 
individuals may die before blood samples for biomarkers can be obtained, or before 
elevated cardiac biomarkers can be identified. If patients present with clinical features 
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of myocardial ischaemia, or with presumed new ischaemic ECG changes, they should 
be classified as having had a fatal MI, even if cardiac biomarker evidence of MI is 
lacking[7]. 
Myocardial infarction associated with revascularization procedures (MI types 4 
and 5) 
Periprocedural myocardial injury or infarction may occur at some stages in the 
instrumentation of the heart that is required during mechanical revascularization 
procedures, either by PCI or by coronary artery bypass grafting (CABG). Elevated cTn 
values may be detected following these procedures, since various insults may occur 
that can lead to myocardial injury with necrosis. It is likely that limitation of such 
injury is beneficial to the patient: however, a threshold for a worsening prognosis, 
related to an asymptomatic increase of cardiac biomarker values in the absence of 
procedural complications, is not well defined. Subcategories of PCI-related MI are 
connected to stent thrombosis and restenosis that may happen after the primary 
procedure[8]. 
 
Fig 2: Clinical classification of myocardial infarction 
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Pathophysiology of myocardial infarction  
Initiating events in MI  
Post-mortem examinations after MI almost invariably show advanced coronary 
atherosclerosis with a thrombotic occlusion in one vessel. ‘Sudden ischaemic death’ 
within an hour or so of the onset of symptoms, before infarction proper can develop, 
also occurs. This is probably due to ventricular fibrillation. However, these patients 
usually also have obstructive lesions[1].  
Stress-induced acute abnormalities in both clotting factors and platelets have 
been proposed, but it is currently thought that a particularly lipid-rich plaque, with low 
amounts of smooth muscle and fibrous support, may fissure or rupture. This exposes 
lipid and sub-endothelial structures, triggering massive platelet aggregation and 
subsequent thrombosis. In the few cases where no substantial atheroma is found on 
angiography or at post-mortem examination, the cause may be severe vasospasm or a 
primary platelet or clotting abnormality[1].  
Severity of MI 
Ischaemia is a deficiency of blood supply to tissues, if the deficiency is 
sufficiently severe and prolonged, the tissue eventually necrosis. The most common 
general cause is a failure of blood flow resulting from obstruction or cardiovascular 
insufficiency[1].  
When arteries are chronically inflamed (arteritis), the artery wall may be 
permanently damaged by the neutrophil infiltration and necrosis. If this involves small 
arteries, the entire arterial wall is affected and complete occlusion of the lumen may 
occur. If a larger artery is affected, only part of the wall may be damaged and blood is 
still able to pass. Healing subsequently occurs with the formation of scar tissue, which 
may weaken the artery wall and produce an aneurysm (bulge) that may eventually 
rupture. A common cause of vascular obstruction is atherosclerosis, which affects the 
intimal lining of the artery wall, particularly in medium to large arteries. Atheromatous 
plaques are laid down that partially occlude the lumen and become sites for thrombus 
formation. In contrast, arteriosclerosis affects the media of the arterial wall, which 
becomes hard and inelastic and small arterioles may become occluded[1].  
A thrombus (blood clot) may be formed over the site of an atheromatous plaque 
in an artery. Thrombi may also form in large veins, usually in the region of valves, 
owing to stasis of blood. If a venous thrombus in the leg (deep-vein thrombosis), or a 
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fragment of it, breaks away from its site of formation, it will travel downstream 
through veins of increasing diameter, through the heart and into the pulmonary tree, 
until it lodges in a small artery. This obstruction to the circulation is known as an 
embolus, i.e. a clot or clot fragment derived from a blood clot formed at one site, which 
lodges in another. Because it is often impossible to distinguish between an embolus 
and a thrombus, and because it does not affect treatment, it is usual to speak of 
thromboembolic disease[1].  
The site of formation of the original clot determines the organ eventually 
affected, which may be predicted on the basis of the anatomy of the vascular tree. 
Emboli can also be due to air introduced into the bloodstream in advertently during IV 
therapy (air embolus) or may be the result of deep diving, causing nitrogen emboli if 
the diver rises to the surface too rapidly, causing the divers’ syndrome known as the 
bends. Fat droplets released from the site of a fracture (fat embolus) do not cause an 
infarction as such, but can result in a severe interruption of gas exchange if deposited 
in the lung. Thrombosis in a coronary artery may itself cause a myocardial infarction 
or may throw off an embolus that travels further into the coronary arterial tree to 
obstruct a smaller vessel and so affect a smaller area of heart muscle. Emboli formed 
on damaged heart valves can reach the retina, affecting sight, whereas those resulting 
from atrial fibrillation tend to cause strokes by occluding a cerebral artery[1].  
Small thrombo emboli are quite quickly dissolved by natural clot-dissolving 
factors derived from blood plasminogen (plasmin), red cells and vessel walls, e.g. 
tissue-type plasminogen activator. Temporary interruptions of CNS function, known 
as transient ischaemic attacks (TIAs), are common and usually last less than 15 min, 
but may persist for up to 24 h. Circulatory brain obstructions of longer duration are 
classed as strokes[1].  
Acute MI is treated in the early stage with fibrinolytic (thrombolytic) drugs, 
e.g. alteplase, reteplase, tenectoplase and streptokinase, and the latter is also used in 
several other thromboembolic situations. All of these are unsuitable for use in early 
stroke unless it is certain that the stroke has not been caused by a cerebral haemorrhage, 
which would be exacerbated by clot dissolution. Constriction of the vascular smooth 
muscle(vasospasm) may occur in coronary arteries, as in variant angina and in 
peripheral arteries, causing Raynaud’s disease. Poor perfusion of tissue may also arise 
from circulatory insufficiency. If cardiac output is low because of heart failure or 
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arrhythmia, the blood supply to many tissues will be reduced. This may also occur if 
the blood volume is low, perhaps following severe blood loss, causing shock. 
 If a tissue undergoes a period of anoxia, then irreversible damage occurs, 
followed by wound healing and organization of scar tissue. Scar tissue can never fulfil 
the functions of the tissue it replaces. In the heart, this means that as well as being 
noncontractile, the infarcted area is inelastic and poorly conducting. This has the 
following potential consequences: 
• Poor contractility leads to poor ejection, i.e. systolic failure. 
• Poor elasticity (reduced compliance) leads to poor filling, i.e. diastolic failure. 
• Poor conductivity leads to arrhythmias. 
The consequences in individual cases depend primarily on the size of the area 
of myocardium served by the coronary vessel that is occluded. The mildest form 
involves a small arteriole, resulting in a clinically silent (symptomless) infarction. 
Moreover, dilatation of neighbouring vessels by autoregulation may protect there an 
adjacent to the ischaemic core from complete anoxia, thereby limiting infarct size. 
However, if this is repeated over a long period it results in widespread ‘patchy fibrosis’ 
and eventual cardiac failure. Occlusion of larger arterioles will cause a classical 
presentation of MI, but if there a damaged is not too extensive the patient will survive, 
possibly with a degree of permanent cardiac failure. At its most severe an MI may 
involve one of the main coronary arteries, often the left anterior descending, which 
supplies most of the left ventricle, causing an anterior infarct. Death is likely if more 
than about 50% of the left ventricle is damaged[1]. 
One important factor determining outcome is how well developed the patient’s 
collateral coronary vessels are; another is how much conducting tissue is involved. 
Conduction across the whole myocardium is necessary for normal coordinated 
contraction, and ischaemic muscle may conduct erratically. In addition, ischaemic 
damage to nodal tissue or nerve tracts may have a disproportionate effect because 
arrhythmias can compromise the function of the entire heart[1]. 
7 
 
 
Fig 3: Pathophysiology of MI 
Etiology of myocardial infarction 
Myocardial infarction (MI) results from lack of oxygen supply to the working 
myocardium. Regional infarcts are due to lack of blood flow that occurs when an 
epicardial artery is blocked by atheroma or thrombus, or other obstructions. Global 
subendocardial infarcts occur when there is lack of oxygenation despite circulation for 
example, when there is a respiratory arrest followed by prolonged hypoxemia[9]. 
Cardiac markers in the diagnosis of myocardial infarction  
The analysis of cardiac biomarkers has become the frontline diagnostic tools 
for AMI, and has greatly enabled the clinicians in the rapid diagnosis and prompt 
treatment planning, thereby reducing the mortality rate to a great extent[10].  
• Creatine kinase  
• Lactate dehydrogenase (LDH) 
• Troponins 
• Myoglobin 
Creatine kinase 
It is an enzyme chiefly found in the brain, skeletal muscles, and heart. An 
elevated level of creatine kinase is seen in heart attacks, when the heart muscle is 
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damaged, or in conditions that produce damage to the skeletal muscles or brain. There 
are three different forms of creatine kinase that can be measured[10]. 
• CK-MM (located in the skeletal muscles and heart) 
• CK-MB (mainly located in the heart) 
• CK-BB (located in the brain)  
An elevated level of creatine kinase, specifically CK-MB, occurs within hours 
of a heart attack as the heart muscle cells die. The enzyme level continues to rise for 
the first 18 to 24 hours after a heart attack and slowly returns to normal after a few 
days[10].  
Trauma and other conditions that damage the skeletal muscle are also 
associated with an elevated creatine kinase level. In some cases, the test may be used 
to detect muscle conditions such as polymyositis (condition characterized by the 
inflammation of muscles) or to estimate the degree of muscle damage. Stroke and other 
forms of brain damage can also result in an elevated creatine kinase level[10]. 
             Creatine kinase (CK) has several functions in cellular energy metabolism. It 
catalyzes the reversible transfer of high-energy phosphate from ATP to creatine, 
facilitating storage of energy in the form of phosphocreatine. In muscle cells, this extra 
energy buffer plays a pivotal role in maintaining ATP homeostasis[10]. 
       Lactate dehydrogenase 
Lactate dehydrogenase (LDH) is an enzyme present in many different cells. 
There are five isoenzymes, each with different specificities for different types of tissue. 
In the case of cardiac injury, LDH isoenzyme1 is higher than isoenzyme-II. But under 
normal circumstances, isoenzyme II is present in greater amounts than isoenzyme I. 
The LDH starts going up in 12-24 hours following an MI, and it dissipates within a 
week or two. This test has been supplanted by the other markers[10].  
Troponins 
               Troponins are the best overall markers; they have the best combination of 
sensitivity, specificity, and ease of test performance of all the markers. They are 
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complex of 3 protein subunits located on the thin filaments of the skeletal and cardiac 
muscle fibers. They are; 
• Troponin C -Calcium-binding component in the skeletal and cardiac 
muscle, but it is not extremely specific for myocardial injury.  
• Troponin T - Tropomyosin-binding component 
• Troponin I - Inhibitory component 
             The isoforms of troponin-T and troponin-I differ in the skeletal and the cardiac 
muscle, and thus are extremely specific for cardiac tissue necrosis. Troponin-T is 
present chiefly in the bound form to the contractile elements of the myocardial cells 
and it is also present free in the cytoplasm[10].  
           Troponin-T exhibits a dual release initially of the cytoplasmic component and 
later of the bound component. Troponin-I is extremely specific for the cardiac muscle 
and has not been isolated from the skeletal muscle. This absolute specificity makes it 
an ideal marker of myocardial injury. They are released into the circulation 6-8h after 
myocardial injury, peak at 12-24h and remain elevated for 7-10days[10].  
           Troponins are components of cardiac muscle that are released into the blood 
when myocardial cells are injured. They are very specific for myocardial muscle – 
even more specific than CK-MB. Troponins go up within 3-12 hours after the onset of 
MI[10].  
Myoglobin (MYO) 
              Myoglobin is a small cytoplasmic oxygen-binding protein found in the 
skeletal as well as the cardiac muscle. It is released extremely early into the serum, 1h 
after the onset of myocardial injury, peaks at 4-12h and returns to baseline values 
immediately[10].  
               The major disadvantage of myoglobin is the lack of specificity to the 
cardiac tissue due to the presence of large amounts of MYO in the skeletal muscle. 
The levels of MYO can therefore not be used as a single diagnostic marker, but in 
conjunction with the troponins or CK-MB. Thus, serum levels of MYO can be used to 
rule out, rather than diagnose, myocardial infarction[10]. 
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Role of liver enzymes related to myocardial infarction 
ALT means alanine transaminase, it is a liver enzyme. ALT helps to metabolize 
protein. This liver enzyme become release into bloodstream when liver becomes 
damage. An increase level of ALT into blood may indicate hepatic disorder, liver 
tumor, infection or toxic hepatitis. Acute hemolytic anemia, myocardial infarction also 
may occur due to elevated level of liver enzyme into blood[10]. 
ALP means alkaline phosphatase, it is another liver enzyme. This liver enzyme 
needed little amount for trigger specific chemical reaction. ALP normally present in 
liver, bone, kidney and intestine. Elevated level of ALP may indicate gallstone disease, 
drug induce hepatitis or biliary tumors[10]. 
AST means Aspartate transaminase. This liver enzyme plays an important role 
in the metabolism of amino acid alanine. Elevated level of AST may indicate active 
cirrhosis disease, infection or toxic hepatitis or acute hemolytic anemia. Crushing 
injuries, heart attack and tumor can occur due to increase of liver enzyme into blood10. 
Management of myocardial infarction 
• Act promptly to save life and reduce complications 
• Treat acute symptoms 
• Restore flow through the affected artery (revascularization) 
• Minimize subsequent infarct size 
• Treat complications 
• Rehabilitate 
• Ensure secondary prevention of subsequent 
Initial therapy for acute myocardial infarction is directed toward restoration of 
perfusion as soon as possible to salvage as much of the jeopardized myocardium as 
possible. This may be accomplished through medical or mechanical means, such 
as percutaneous coronary intervention or coronary artery bypass grafting[11]. 
Further treatment is based on; 
• Restoration of the balance between the oxygen supply and demand to prevent 
furtherr ischemia 
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• Pain relief 
• Prevention and treatment of any complications that may arise. 
Thrombolytic therapy has been shown to improve survival rates in patients 
with acute myocardial infarction if administered in a timely fashion in the appropriate 
group of patients. If percutaneous coronary intervention (PCI) capability is not 
available or will cause a delay greater than 90 minutes, then the optimal approach is to 
administer thrombolytics within 12 hours of onset of symptoms in patients with ST-
segment elevation greater than 0.1 mV in 2 or more contiguous ECG leads, new left 
bundle-branch block (LBBB), or anterior ST depression consistent with posterior 
infarction. Tissue plasminogen activator is superior to streptokinase in achieving a 
higher rate of coronary artery patency; however, the key to efficacy lies in the speed 
of the delivery of therapy[11]. 
Aspirin and antiplatelet therapy  
Aspirin has been shown to decrease mortality and re-infarction rates after 
myocardial infarction. Administer aspirin immediately, which the patient should chew 
if possible upon presentation. Continue aspirin indefinitely unless an obvious 
contraindication, such as a bleeding tendency or an allergy, is present. Clopidogrel 
may be used as an alternative in cases of a resistance or allergy to aspirin. Clopidogrel 
as Adjunctive Reperfusion Therapy Thrombolysis in Myocardial Infarction suggest 
that adding clopidogrel to this regimen is safe and effective[11].  
Heparin and other anticoagulant agents 
Heparin has an established role as an adjunctive agent in MI patients, Heparin 
is also indicated in patients undergoing primary angioplasty. Few data exist with 
regard to efficacy in patients not receiving thrombolytic therapy in the setting of acute 
myocardial infarction. Bivalirudin (a direct thrombin inhibitor) has shown some 
promise in the setting of STEMI if combined with high-dose clopidogrel load and may 
be an appropriate alternative strategy[11].  
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Nitrates 
Nitrates have no apparent impact on mortality rate in patients with ischemic 
syndromes. Their utility is in symptomatic relief and preload reduction. Administer to 
all patients with acute myocardial infarction within the first 48 hours of presentation, 
unless contraindicated (ie, in RV infarction)[11].  
ACE inhibitors 
They reduce mortality rates after myocardial infarction. Administer ACE 
inhibitors as soon as possible as long as the patient has no contraindications and 
remains in stable condition. They have the greatest benefit in patients with ventricular 
dysfunction. Continue ACE inhibitors indefinitely after myocardial infarction. 
Angiotensin-receptor blockers may be used as an alternative in patients who develop 
adverse effects, such as a persistent cough, although initial trials need to be 
confirmed[11].  
Beta-blockers 
They reduce the rates of reinfarction and recurrent ischemia. Administer to 
patients with myocardial infarction unless a contraindication is present. 
However, a large chinese trial showed no benefit to beta-blockade. This has created 
some doubt as to the benefit and may lead to a change in the guidelines[11].  
Role of free-radicals and anti-oxidants in myocardial infarction 
The role of free radicals in mediating myocardial tissue injury during 
myocardial ischemia and in particular during the phase of myocardial re-oxygenation. 
Associated with myocardial ischemia and reperfusion is the generation of oxygen-
derived free radicals from a variety of sources that include the mitochondrial electron 
transport chain; the biosynthesis of prostaglandins; the enzyme xanthine oxidase; and 
circulating elements in the blood, with the polymorphonuclear neutrophil assuming a 
primary focus of attention[12]. 
Free radicals contain one or more of unpaired electrons. They play an important 
role in the pathogenesis of tissue damage in many clinical disorders. Oxygen free 
radicals are capable of damaging compounds of all biochemical classes; including 
nucleic acids, proteins, lipids, lipoproteins, carbohydrates and connective tissue 
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macromolecules (1). Normally, there is a balance between tissue oxidant and 
antioxidant activity. The latter is achieved by the antioxidant scavenger system, which 
includes enzymes like superoxide dismutase (SOD), catalase, glutathione peroxidase 
(GPx) and antioxidant vitamins (C, A, E and other carotenoids) (2). Oxidative stress 
is a condition in which oxidant metabolites exert their toxic effect because of an 
increased production or an altered cellular mechanism[13]. 
Experimental studies have shown that free radical scavengers (e.g., N-[2-
mercaptopropionyl] glycine) and enzymes that scavenge or degrade reactive species 
of oxygen (superoxide dismutase or catalase) can reduce the mass of myocardial tissue 
that undergoes irreversible injury. Additionally, allopurinol, which inhibits the enzyme 
xanthine oxidase, reduces ultimate infarct size, putatively by reducing the xanthine 
oxidase generation of superoxide anion. Neutrophils that enter the ischemically injured 
myocardium under the influence of chemotactic attraction and activation of the 
complement system generate and release highly reactive and cytotoxic oxygen 
derivatives that are destructive to the vascular endothelium and to the cardiac 
myocytes[12]. 
Biological activity of flavonoids  
They are group of polyphenolic compounds having benzo-𝞬-pyrone structure 
and are present in plants. They are synthesized by phenyl-propanoid pathway. They 
are hydroxylated phenolic substances and are known to be synthesized by plants in 
response to microbial infection. Their activities are structure dependent. The chemical 
nature of flavonoids depends on their structural class, degree of hydroxylation, other 
substitutions and conjugations, and degree of polymerization[13]. 
Recent interest in these substances has been stimulated by the potential health 
benefits arising from the antioxidant activities of these polyphenolic compounds. 
Functional hydroxyl groups in flavonoids mediate their antioxidant effects by 
scavenging free radicals or by chelating metal ions. The chelation of metals could be 
crucial in the prevention of radical generation which damage target biomolecules. As 
a dietary component, flavonoids are thought to have health-promoting properties due 
to their high antioxidant capacity both in vivo and in vitro systems. Flavonoids have 
ability to induce human protective enzyme systems[13].  
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The number of studies has suggested protective effects of flavonoids against 
many infectious like bacterial and viral diseases, degenerative diseases such as 
cardiovascular diseases, cancers, and other age-related diseases[13].  
Flavonoids also act as a secondary antioxidant defence system in plant tissues 
exposed to different abiotic and biotic stresses. Flavonoids are located in the nucleus 
of mesophyll cells and within centres of ROS generation. They also regulate growth 
factors in plants such as auxin. Biosynthetic genes have been assembled in several 
bacteria and fungi for enhanced production of flavonoids[13].  
Chemistry of flavonoids  
 
    Fig 4: Basic nucleus of flavonoids 
Flavonoids are a group of natural compounds with variable phenolic structures 
and are found in plants. In 1930 a new substance was isolated from oranges. At that 
time it was believed to be a member of a new class of vitamins and was designated as 
vitamin P. Later on it became clear that this substance was a flavonoid (rutin) and till 
now more than 4000 varieties of flavonoids have been identified[13].  
Chemically flavonoids are based upon a fifteen-carbon skeleton consisting of 
two benzene rings (A and B) linked via a heterocyclic pyran ring (C). The various 
classes of flavonoids differ in the level of oxidation and pattern of substitution of the 
C ring, while individual compounds within a class differ in the pattern of substitution 
of the A and B rings[13].  
Flavonoids occur as aglycones, glycosides, and methylated derivatives. The 
basic flavonoid structure is aglycone. Six-member ring condensed with the benzene 
ring is either a ߙ-pyrone (flavonols and flavanones) or its dihydroderivative (flavonols 
and flavanones). The position of the benzenoid substituent divides the flavonoid class 
into flavonoids (2-position) and iso0-flavonoids (3-position). Flavonols differ from 
flavanones by hydroxyl group at the 3-position and a C2–C3 double bond[13].  
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Flavonoids are often hydroxylated in positions 3, 5, 7, 2, 3, 4, and 5. Methyl 
ethers and acetyl esters of the alcohol group are known to occur in nature. When 
glycosides are formed, the glycosidic linkage is normally located in positions 3 or 7 
and the carbohydrate can be L-rhamnose, D-glucose, gluco-rhamnose, galactose, or 
arabinose[13].  
Importance of flavonoids in plants  
Flavonoids are a group of natural compounds with variable phenolic structures 
and are found in plants. In 1930 a new substance was isolated from oranges. At that 
time it was believed to be a member of a new class of vitamins and was designated as 
vitamin P. Later on it became clear that this substance was a flavonoid (rutin) and till 
now more than 4000 varieties of flavonoids have been identified. They are a major 
colouring component of flowering plants. Flavonoids are an integral part of human and 
animal diet. Flavonoids cannot be synthesized by humans and animals. Thus 
flavonoids found in animals are of plant origin rather than being biosynthesized in 
situ[13].  
Flavonols are the most abundant flavonoids in foods. Flavonoids in food are 
generally responsible for colour, taste, prevention of fat oxidation, and protection of 
vitamins and enzymes. Flavonoids found in the highest amounts in the human diet 
include the soy isoflavones, flavonols, and the flavones. They exhibit several 
pharmacological activities such as anti-allergic, anti-inflammatory, anti-microbial, 
anti-oxidant, cardioprotective, neuroprotective, hepatoprotective, anti-carcinogenic, 
anti-HIV property. Available reports tend to show that secondary metabolites of 
phenolic nature including flavonoids are responsible for the variety of pharmacological 
activities. They are hydroxylated phenolic substances and are known to be synthesized 
by plants in response to microbial infection[13]. 
 The chemical nature of flavonoids depends on their structural class, degree of 
hydroxylation, other substitutions and conjugations, and degree of polymerization. 
Recent interest in these substances has been stimulated by the potential health benefits 
arising from the antioxidant activities of these polyphenolic compounds[13].  
Functional hydroxyl groups in flavonoids mediate their antioxidant effects by 
scavenging free radicals or by chelating metal ions. The chelation of metals could be 
crucial in the prevention of radical generation which damage target biomolecules. As 
a dietary component, flavonoids are thought to have health-promoting properties due 
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to their high antioxidant capacity both in vivo and in vitro systems. Flavonoids have 
ability to induce human protective enzyme systems[13].  
The number of studies has suggested protective effects of flavonoids against 
many infectious (bacterial and viral diseases) and degenerative diseases such as 
cardiovascular diseases, cancers, and other age-related diseases. The mechanisms 
involved in protection provided by flavonoids are described separately in this review. 
Flavonoids also act as a secondary antioxidant defence system in plant tissues exposed 
to different abiotic and biotic stresses[13].  
Flavonoids are located in the nucleus of mesophyll cells and within centers of 
ROS generation. They also regulate growth factors in plants such as auxin. 
Biosynthetic genes have been assembled in several bacteria and fungi for enhanced 
production of flavonoids. This review deals with the structural aspects of flavonoids 
and their protective roles against many human diseases[13]. 
Classification of flavonoids  
Over 5000 naturally occurring flavonoids have been characterized from 
various plants. Flavonoids can be divided in to variety of classes such as  
• Flavone (flavone, apigenin, and luteolin) 
• Flavonol (quercetin, kaempferol, myricetin, and fisetin) 
• Flavanone (flavanone, hesperedin, and naringenin) 
• Isoflavone 
• Anthocyanidin 
Pharmacological actions of flavonoids 
• Antioxidant Activity 
• Lipid peroxidation 
• Hepatoprotective Activity 
• Anti-Inflammatory Activity 
• Anticancer Activity 
• Antiviral Activity 
Antioxidant Activity  
Antioxidant Activity of flavonoids depends upon the arrangement of functional 
groups about the nuclear structure. The configuration, substitution, and total number 
of hydroxyl groups substantially influence several mechanisms of antioxidant activity 
such as radical scavenging and metal ion chelation ability. The B ring hydroxyl 
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configuration is the most significant determinant of scavenging of ROS and RNS 
because it donates hydrogen and an electron to hydroxyl, peroxyl, and peroxy-nitrite 
radicals, stabilizing them and giving rise to a relatively stable flavonoids radical. 
Mechanisms of antioxidant action can include suppression of ROS formation either by 
inhibition of enzymes or by chelating trace elements involved in free radical 
generation; scavenging ROS; and upregulation or protection of antioxidant defences13.  
Flavonoid action involves most of the mechanisms mentioned above. Some of 
the effects mediated by them may be the combined result of radical scavenging activity 
and the interaction with enzyme functions. Flavonoids inhibit the enzymes involved in 
ROS generation, that is, microsomal monooxygenase, glutathione S-transferase, 
mitochondrial succin-oxidase, NADH oxidase[14]. 
Lipid peroxidation in MI 
It is a common consequence of oxidative stress. Flavonoid protect lipids 
against oxidative damage by various mechanisms. Free metal ions enhance ROS 
formation by the reduction of hydrogen peroxide with generation of the highly reactive 
hydroxyl radical. Due to their lower redox potentials flavonoids (Fl-OH) are 
thermodynamically able to reduce highly oxidizing free radicals, such as superoxide, 
peroxyl, alkoxyl, and hydroxyl radicals by hydrogen atom donation. Because of their 
capacity to chelate metal ions (iron, copper, etc.), flavonoids also inhibit free radical 
generation. Quercetin in particular is known for its iron-chelating and iron-stabilizing 
properties. Trace metals bind at specific positions of different rings of flavonoid 
structures. The binding sites -catechol structure in the B ring firmly enhances 
inhibition of lipid peroxidation. This trait of flavonoids makes them most effective 
scavengers of peroxyl, superoxide, and Peroxy-nitrite radicals[15]. 
Epicatechin and rutin are strong radical scavengers and inhibitors of lipid 
peroxidation in vitro. Because of oxidation on the B ring of flavonoids having catechol 
group a fairly stable ortho- semiquinone radical is formed which is strong scavengers. 
Flavones lacking catechol system on oxidation lead to formation of unstable radicals 
exhibit weak scavenging potential. The literature shows that flavonoids having an 
unsaturated 2-3 bond in conjugation with a 4-oxo function are more potent antioxidants 
than the flavonoids lacking one or both features. Conjugation between the A and B 
rings allows a resonance effect of the aromatic nucleus that provides stability to the 
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flavonoid radical. Free radical scavenging by flavonoids is potentiated by the presence 
of both the elements besides other structural features[15]. 
Hepatoprotective activity 
Hepatoprotective activity of several flavonoids such as catechin, apigenin, 
quercetin, naringenin, rutin, and venoruton are reported for their hapatoprotective 
activities. Different chronic diseases such as diabetes may lead to development of 
hepatic clinical manifestations. glutamate-cysteine ligase catalytic subunit (Gclc) 
expression, glutathione, and ROS levels are reported to be decreased in liver of 
diabetic mice. Anthocyanins have drawn increasing attention because of their 
preventive effect against various diseases demonstrated that anthocyanin cyanidin-3-
O-ߚ- glucoside (C3G) increases hepatic Gclc expression by increasing cAMP levels 
to activate protein kinase A (PKA), which Antibacterial Activity. Flavonoids are 
known to be synthesized by plants in response to microbial infection; thus, it should 
not be surprising that they have been found invitro to be effective antimicrobial 
substances against a wide array of microorganisms. Flavonoid rich plant extracts from 
different species have been reported to possess antibacterial activity. Several 
flavonoids including apigenin, galangin, flavone and flavonol glycosides, isoflavones, 
flavanones, and chalcones have been shown to possess potent antibacterial activity[16]. 
Anti-Inflammatory Activity 
Inflammation is a normal biological process in response to tissue injury, 
microbial pathogen infection, and chemical irritation. Inflammation is initiated by 
migration of immune cells from blood vessels and release of mediators at the site of 
damage. This process is followed by recruitment of inflammatory cells, release of 
ROS, RNS, and proinflammatory cytokines to eliminate foreign pathogens, and 
repairing injured tissues. In general, normal inflammation is rapid and self-limiting, 
but aberrant resolution and prolonged inflammation cause various chronic 
disorders[17]. 
Anticancer Activity 
 Dietary factors play an important role in the prevention of cancers. Fruits and 
vegetables having flavonoids have been reported as cancer chemo preventive agents. 
Consumption of onions and/or apples, two major sources of the flavonol quercetin, is 
inversely associated with the incidence of cancer of the prostate, lung, stomach, and 
breast. In addition, moderate wine drinkers also seem to have a lower risk to develop 
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cancer of the lung, endometrium, oesophagus, stomach, and colon. The critical 
relationship of fruit and vegetable intake and cancer prevention has been thoroughly 
documented. It has been suggested that major public health benefits could be achieved 
by substantially increasing consumption of these foods[18]. 
Major molecular mechanisms of action of flavonoids are given as follows: 
• Downregulation of mutant p53 protein 
• Cell cycle arrest 
• Tyrosine kinase inhibition 
• Inhibition of heat shock proteins 
• Estrogen receptor binding capacity 
• Inhibition of expression of Ras proteins 
Antiviral Activity 
Natural compounds are an important source for the discovery and the 
development of novel antiviral drugs because of their availability and expected low 
side effects. Naturally occurring flavonoids with antiviral activity have been 
recognized since the 1940s and many reports on the antiviral activity of various 
flavonoids are available. Search of effective drug against human immune deficiency 
virus (HIV) is the need of hour. Most of the work related with antiviral compounds 
revolves around inhibition of various enzymes associated with the life cycle of viruses. 
Structure function relationship between flavonoids and their enzyme inhibitory 
activity has been observed. Gerdin and Srensso demonstrated that flavan-3-o1 was 
more effective than flavones and flavonones in selective inhibition of HIV-1, HIV-2, 
and similar immunodeficiency virus infections. Baicalin, a flavonoid isolated from 
Scutellaria baicalensis (Lamieaceae), inhibits HIV-1 infection and replication[19]. 
Cardioprotective activity 
Recent, flavonoids have been stimulated by the potential health benefits arising 
from the antioxidant activity of those ployphenolic compounds. The results of their 
high propensity to transfer electrons, chelate ferrous ions, and scavenge reactive 
oxygen species. Because of these properties, flavonoids have been considered as 
potential protectors against chronic cardiotoxicity caused by the cytostatic drug 
doxorubicin. Doxorubicin is a very effective antitumor agent but its clinical use is 
limited by the occurrence of a cumulative dose-related cardiotoxicity, resulting in, for 
example, congestive heart failure (negative inotropic effect) In a recent report, the 
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cardiotoxicity of doxorubicin on the mouse left atrium has been inhibited by 
flavonoids, 7- monohydroxyethylrutoside and 7,3,4-trihydroxyethylrutoside[20]. 
Antiulcer activity 
Flavonoids possess anti-ulcerogenic activity. Flavonoid glycosides decreased 
ulcer   and inhibited gastric acid and pepsin secretions. Quercetin, rutin, and 
kaempferolare used for the treatment of peptic ulcer.[20-23]  
Endocrine effects of flavonoids 
Flavonoids exhibit hormone like activities. They show similar action to 
oestrogen and other steroid hormones and are referred to as phytoestrogens. Genistein, 
daidzein and equal are used for treatment of chronic diseases such as hormone-
dependent cancer, cardiovascular disorders and osteoporosis. Genistein is the most 
promising compound to prevent postmenopausal bone loss in women. Flavonoids are 
also known to exhibit anti-thyroid effects in animals and humans. Genistein help in the 
maintenance of insulin, thyroid hormones, adrenocorticotropic hormone, cortisol and 
corticosterone level, as well as lipid metabolic changes[24]. 
Drug discovery and development  
Drug discovery and development is a research process that identifies a new 
chemical. Drug discovery is the area of research in which chemo-informatics has found 
the greatest application. Traditional pharmaceutical industry would require 12-14 
years and costing up to $1.2 - $1.4 billion to bring a drug from discovery to market, in 
this approach drugs were discovered by synthesizing compounds in a time-consuming 
multi-step processes with failures attributed to poor pharmacokinetics (39%), lack of 
efficacy (30%), animal toxicity (11%), adverse effects in humans (10%) and various 
commercial and miscellaneous factors[25].  
Today, the process of drug discovery has been revolutionized with the advent 
of genomics, proteomics, bioinformatics and efficient technologies like, combinatorial 
chemistry, cheminformatics, high throughput screening (HTS), virtual screening, de 
novo design, in vitro, in silico ADMET screening, Quantitative structure-activity 
relationship (QSAR) and structure-based drug design[25].  
The process of finding a new drug against a chosen target for a particular 
disease usually involves high-throughput screening (HTS), wherein large libraries of 
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chemicals are tested for their ability to modify the target. The primary application of 
cheminformatics is in the storage of information related to the drug molecules and the 
efficient presentation of such stored information during the process of lead 
optimization[25]. 
A range of parameters can be used to assess the quality of a compound, or a 
series of compounds, as proposed in the Lipinski's Rule of Five. Such parameters 
include calculated properties such as C Log P to estimate lipophilicity, rotatable bonds 
to estimate molecular flexibility, molecular weight, Hydrogen Bond Acceptors and 
Hydrogen Bond Donors to estimate Pharmacophoric Properties, polar surface area and 
measured properties, such as potency, in-vitro measurement of enzymatic clearance 
etc. Some descriptors such as ligand efficiency (LE) and lipophilic efficiency (LiPE) 
combine such parameters to assess drug likeness[26]. 
Importance of molecular docking  
Pharmaceutical research has successfully incorporated a wealth of molecular 
modelling methods, within a variety of drug discovery programs, to study complex 
biological and chemical systems. The integration of computational and experimental 
strategies has been of great value in the identification and development of novel 
promising compounds. Broadly used in modern drug design, molecular docking 
methods explore the ligand conformations adopted within the binding sites of 
macromolecular targets. This approach also estimates the ligand-receptor binding free 
energy by evaluating critical phenomena involved in the intermolecular recognition 
process[25].  
Molecular docking has become an increasingly important tool for drug 
discovery. Flexible receptor molecular docking approaches, especially those including 
backbone flexibility in receptors, are a challenge for available docking methods. A 
recently developed Local Move Monte Carlo (LMMC) based approach is introduced 
as a potential solution to flexible receptor docking problems. Three application 
examples of molecular docking approaches for drug discovery are provided[25]. 
                 The molecular docking approach can be used to model the interaction 
between a small molecule and a protein at the atomic level, which allow us to 
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characterize the behavior of small molecules in the binding site of target proteins as 
well as to elucidate fundamental biochemical processes[25].  
Knowing the location of the binding site before docking processes significantly 
increases the docking efficiency. In many cases, the binding site is indeed known 
before docking ligands into it. Also, one can obtain information about the sites by 
comparison of the target protein with a family of proteins sharing a similar function or 
with proteins co-crystallized with other ligands. In the absence of knowledge about the 
binding sites, cavity detection programs or online servers, e.g. GRID[27,28], 
POCKET[29], SurfNet[30,31], PASS[32] and MMC[33] can be utilized to identify putative 
active sites within proteins. Docking without any assumption about the binding site is 
called blind docking[25]. 
Theory of docking 
Essentially, the aim of molecular docking is to give a prediction of the ligand-
receptor complex structure using computation methods. Docking can be achieved 
through two interrelated steps: first by sampling conformations of the ligand in the 
active site of the protein; then ranking these conformations via a scoring function. 
Ideally, sampling algorithms should be able to reproduce the experimental binding 
mode and the scoring function should also rank it highest among all generated 
conformations. From these two perspectives, we give a brief overview of basic docking 
theory[25]. 
Molecular Docking  
Molecular docking is one of the most frequently used methods in SBDD 
because of its ability to predict, with a substantial degree of accuracy, the conformation 
of small-molecule ligands within the appropriate target binding site. Following the 
development of the first algorithms in the1980s, molecular docking became an 
essential tool in drug discovery. For example, investigations involving crucial 
molecular events, including ligand binding modes and the corresponding 
intermolecular interactions that stabilize the ligand-receptor complex, can be 
conveniently performed. Furthermore, molecular docking algorithms execute 
quantitative predictions of binding energetics, providing rankings of docked 
compounds based on the binding affinity of ligand-receptor complexes[25]. 
The docking process involves two basic steps:  
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• Prediction of the ligand conformation as well as its position and orientation 
within the sites.  
• Assessment of the binding affinity.  
The early elucidation for the ligand-receptor binding mechanism is the lock-
and-key theory[37] in which the ligand fits into the receptor like lock and key. The 
earliest reported docking methods were based on this theory and both the ligand and 
receptor were treated as rigid bodies accordingly.  
 Then the “induced-fit” theory created by Koshland takes the lock-and-key 
theory a step further, stating that the active site of the protein is continually reshaped 
by interactions with the ligands as the ligands interact with the protein. This theory 
suggests that the ligand and receptor should be treated as flexible during docking. 
Consequently, it could describe the binding events more accurately than the rigid 
treatment[35]. 
Lipinski’s rule of Five 
            This rule was postulated by Christopher A. Lipinski in 1997, based on the 
observation that most of the drugs are relatively small and lipophilic in nature. 
Lipinski's rule of five is a rule of thumb to evaluate druglikeness26. This rule states 
that, an orally active "drug-like" molecule has: 
• Partition coefficient (log P) less than 5  
• Molecular weight under 500 daltons 
• Not more than 10 hydrogen bond acceptors (O and Ngroup) 
• Not more than 5 hydrogen bond donors (OH and NH group) 
• Number of violations less than 5 
• All the numbers should be multiples of 5, which is the basis for the rules name. 
 The rule describes about pharmacokinetic properties of a drug in the human 
body, including their absorption, distribution, metabolism, and excretion (ADME). 
But this rule does not predict if a compound is pharmacologically active or not.[38] This 
set of rules suggests that the necessary properties for good oral bioavailability and 
reflects the notion that pharmacokinetics, toxicity and other adverse effects are directly 
linked to the chemical structure of a drug[27].  
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Types of docking[35,36]  
Rigid docking 
 The rigid docking is suitable position for the ligand in receptor environment 
obtained while maintaining its rigidity. 
Flexible docking 
 In this process, receptor-ligand interaction was obtained by changing internal 
torsions of ligand into the active site while receptor remains fixed.  
Docking approaches 
Two approaches mainly popular in molecular docking. 
• Shape complementarity: This technique is used to describe the matching  of 
ligand and protein as complementarity surfaces. 
• Simulation: It is the actual docking process additionally calculating the 
 interaction energies between ligand and protein molecule. 
Mechanics of docking 
 To perform a docking screen, the first requirement is a structure of a protein. 
Protein structure has been determined by using x-ray crystallography or NMR 
spectroscopy. The protein structure and database of potential ligands serve as inputs 
to a docking programme. The success of docking program depends on: search 
algorithm and scoring function[35,36]. 
Search algorithm 
 A strict search algorithm would completely elucidate all possible binding 
modes between ligand and receptor. Various searching algorithms have been 
developed and widely used in molecular docking software.  But it would be too 
expensive to computationally generate all the possible conformations. Some 
commonly used searching algorithms are: Monte Carlo (MC) methods, fragment based 
method, distance geometry, matching method, ligand fit method, point 
complementarity method, blind docking, inverse docking, genetic algorithms and 
molecular dynamics[35,36]. 
Monte Carlo (MC) method 
 Methods are among the most established and widely used stochastic 
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optimization techniques. These methods use sampling technique and are able to 
generate states of low energy conformations. The system makes random moves and 
accepts or rejects each conformation based on Boltzmann probability. Simulated 
annealing is a generalization of a Monte Carlo method for examining the equations of 
state and frozen states of n-body systems. The initial state of the system has random 
thermal motion within a specified potential force field. The effective temperature of 
the system (the degree of random motion) is decreased overtime, until a final stable 
docked position is obtained. The random motion of the ligand allows for exploration 
of the local search space, and the decreasing temperature of the system acts to drive it 
to a minimum energy. One of the most widely used simulated annealing procedures is 
the Metropolis Monte Carlo simulated annealing algorithm[35,36]. 
Fragment based method 
 Fragment based methods can be described as dividing the ligand into separate 
protons or fragments, docking the fragments and finally linking these fragments 
together with target protein. Some mainly used fragment based methods are Flexx[37]. 
Distance geometry 
 Many types of structural information can be expressed as intra or 
intermolecular distances. The distance geometry formalism allows these distances to 
be assembled and 3 dimensional structures consistent with them to be calculated. The 
fast sampling of the conformational space do not always results in reliable results. An 
example of a program using distance geometry in docking problem is Dock It.[37] 
Matching method 
 This method focuses on complementarity. Ligand atom is placed at the ‘best’ 
position in the site, generating a ligand receptor configuration that may require 
optimization.[37] 
Ligand fit method 
 Ligand fit term provide a rapid accurate protocol for docking small molecules 
ligand into protein active sites for considering shape complimentarity between ligand 
and protein active sites.[37] 
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Point complementarity method 
 These methods are based on evaluating a shape and/or chemical 
complementarity between interacting molecule.[37] 
Blind docking 
 It is introduced for detection of possible binding sites and modes of peptide 
ligand by scanning the entire surface of protein targets.[37] 
Inverse docking 
 This method uses computer for finding toxicity and side effects of protein 
targets on a small molecule. Knowledge of these targets combined with that of 
proteomics pharmacokinetic profile can facilitates the assessment of potential 
toxicities side effect of drug candidate. One of these protocols is selected for docking 
studies of particular ligand.[37] 
Genetic algorithm (GA) 
 It is adaptive heuristic search technique premised on the evolutionary ideas of 
natural selection and genetics. The basic concept of GA is designed to simulate 
processes in natural system necessary for evolution, which is akin to the principles first 
laid down by Darwin. As such they represent an intelligent exploitation of a random 
search within a defined search space to solve a problem. In a genetic algorithm, there 
is a population of solutions that undergo mutation and crossover transformations. The 
newly generated solutions undergo selection, biased towards the fit among them. The 
algorithm maintains a selective pressure towards an optimal solution, with a 
randomized information exchange permitting exploration of the search space. A range 
of programs implements GA for docking[37]. 
Molecular dynamics (MD) 
 Molecular dynamics (MD) is widely used as a powerful simulation method in 
many fields of molecular modeling. In the context of docking, by moving each atom 
separately in the field of the rest atoms, MD simulation represents the flexibility of 
both the ligand and protein more effectively than other algorithms. The disadvantage 
of MD simulations is that they progress in very small steps and thus have difficulties 
in stepping over high energy conformational barriers, which may lead to inadequate 
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sampling. MD simulations are often efficient at local optimization. Thus, a current 
strategy is to use random search in order to identify the conformation of the ligand, 
followed by the further subtle MD simulations.[38] 
Scoring functions 
 The purpose of the scoring function is to delineate the correct poses from 
incorrect poses, or binders from inactive compounds in a reasonable computation time. 
Scoring functions involve estimating, rather than calculating the binding affinity 
between the protein and ligand and through these functions, adopting various 
assumptions and simplifications[38]. Scoring functions can be divided into: 
i. Force-field-based scoring functions 
ii. Empirical based scoring functions 
iii. Knowledge-based scoring functions. 
Force-field-based scoring functions 
 Classical Force-field-based scoring functions assess the binding energy by 
calculating the sum of the non-bonded (electrostatics and van der Waals) interactions. 
The electrostatic terms are calculated by a Columbic formulation. Force-field-based 
scoring functions also have the problem of slow computational speed. Thus cut-off 
distance is used to handle the non-bonded interactions. This also results in decreasing 
the accuracy of long-range effects involved in binding[38]. 
 Extensions of force-field-based scoring functions consider the hydrogen bonds, 
solvation’s and entropy contributions. Software programs, such as DOCK, GOLD and 
AutoDock, offer users such functions. They have some differences in the treatment of 
hydrogen bonds, the form of the energy function etc. The results of docking with force-
field-based functions can be further refined with other techniques, such as linear 
interaction energy and free-energy perturbation methods (FEP) to improve the 
accuracy in predicting binding energies[38]. 
Empirical scoring functions 
            In empirical scoring functions, binding energy decomposes into several energy 
components, such as hydrogen bond, ionic interaction, hydrophobic effect and binding 
entropy. Each component is multiplied by a coefficient and then summed up to give a 
final score. Coefficients are obtained from regression analysis fitted to a test set of 
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ligand-protein complexes with known binding affinities. Empirical scoring functions 
may be treated in a different manner by different software, and the numbers of the 
terms included are also different. LUDI, PLP, Chem Score are examples derived from 
empirical scoring functions[38]. 
Knowledge-based scoring functions 
 Knowledge based scoring functions use statistical analysis of ligand-protein 
complexes crystal structures to obtain the inter-atomic contact frequencies and 
distances between the ligand and protein. The scoring is done by statistically observing 
the intermolecular relation between the ligand and the biological target protein using 
“Potential of Mean Force”. The intermolecular interactions are mainly taken into 
account for the functional group or atoms that occur frequently. The result of this 
method is evaluated based on the binding interactions.  
PMF, Drug Score, SMoG and Bleep are examples of knowledge-based functions[38]. 
Various docking software’s 
 Over 60 docking software systems and more than 30 scoring functions are 
reported. Molecular docking is implemented as part of software packages for molecule 
design and simulation. More than one search method and scoring functions are 
provided in order to increase the accuracy of the simulations. Only some of the 
software was made available and a limited number of them are widely used[35].   
DOCK 
           DOCK is one of the oldest and best-known ligand-protein docking programs. It 
systematically describes the geometries of ligands and binding sites by sets of spheres, 
attempting to fit each compound from a database into the binding site and the spheres 
could be overlapped by means of an approximate clique-detection procedure. The 
initial version used rigid ligands and edibility was later incorporated via incremental 
construction of the ligand in the binding pocket of the target protein.  In the recent 
version of DOCK, steric matching-scores with electrostatic and molecular mechanics 
interaction energies are considered for the ligand-receptor complex.  In scoring, the 
docked orientations of atomic hydrophobicity descriptors are being considered[35]. 
GOLD (Genetic Optimization for Ligand Docking) 
 GOLD uses a flexible docking mode for small molecules into protein binding 
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site which utilizes genetic algorithm for the conformational search that forms a 
powerful tool for screening and identification of novel lead compounds. It provides 
docking of flexible ligand and protein with flexible hydroxyl groups. Otherwise the 
protein is considered to be rigid. This makes it a good choice when the binding pocket 
contains amino acids that form hydrogen bonds with the ligand. Gold is very highly 
regarded within the molecular modeling community for its accuracy and reliability and 
its genetic algorithm parameters are optimized for wide range of virtual screening 
applications. GOLD has one of the most comprehensive validation test sets and is also 
available for use at CSC[35,37]. 
FlexX (Future Leaders Exchange) 
 A pose-clustering algorithm is used to classify the docked ligand conformers, 
where the placement of rigid core fragment is based on interaction geometry between 
fragment and receptor groups. Prior to docking, FlexX cuts the ligand at rotatable 
bonds into pieces, places a base fragment into the active site, and incrementally builds 
up the ligand again, using the other pieces. For a protein with known three-dimensional 
structures and a small ligand molecule, FlexX predicts the geometry of the protein-
ligand complex and estimates the binding affinity. It has a bit lower hit rate than DOCK 
but provides better estimates of Root Mean Square Distance for compounds with 
correctly predicted binding mode. There is an extension of FlexX called with flexible 
receptors which has shown to produce better results with significantly lower running 
times[35,37]. 
GLIDE (Grid Based Ligand Docking with Energetics) 
 GLIDE approximates a close and complete systematic search for the 
conformational, orientation and positional space of the docked ligand. Glide uses a 
series of hierarchical filters to search for possible locations of the ligand in the active-
site region of the receptor. A grid representation for the shape and properties of the 
receptor is used that progressively scores for ligand posing[35]. 
SLIDE (Screening for Ligands by Induced-fit Docking) 
 SLIDE represents a general approach to organic and peptidyl database 
screening. It can handle large binding-site templates and uses multi-stage indexing to 
identify feasible subsets of template points for ligand docking. An optimization 
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approach based on mean-field theory is applied to model induced-fit 
complementarities, balancing flexibility between the ligand and the protein side 
chains. SLIDE can screen 100,000 compounds within a few days and returns a ranked 
list of stearically feasible ligand candidates, ranked by complementarities to the 
protein's binding site[35]. 
FRED 
           FRED takes a multi-conformer library or database of one or more ligands, a 
target protein structure, a box defining the active site of the protein and several optional 
parameters. Various options are available for optimization with respect to the built-in 
scoring functions: optimization of hydroxyl group rotamers, rigid body optimization, 
torsion optimization, and reduction of the number of poses that are passed on to the 
next scoring function. The ligand conformers and protein structure are treated as rigid 
during the majority of the docking process. FRED's docking strategy is to exhaustively 
score all possible positions of each ligand in the active site. The exhaustive search is 
based on rigid rotations and translations of each conformer. This novel strategy 
completely avoids the sampling issues associated with stochastic methods used by 
most other docking programs (such as Gold, FlexX, Dock and Glide). FRED jobs can 
also be easily distributed over multiple processors to further reduce docking time[35]. 
Hammerhead 
           Hammerhead is suitable for screening large databases of flexible molecules by 
binding to a protein of known structure. It precisely docks a variety of known flexible 
ligands, and it spends an average of only a few seconds on each compound during a 
screen. The approach is completely automated, from the elucidation of protein binding 
sites, through the docking of molecules, to the final selection of compounds for 
assay[35]. 
AutoDock 
 AutoDock is a script driven flexible automated and random search docking 
technique operated by altering the ligand or a subset of ligand with several rotatable 
bonds to predict the binding interaction between small molecules to the known 
receptor three-dimensional structure. The robustness of AutoDock can be attributed to 
the Monte Carlo simulated annealing, evolutionary, genetic and Lamarckian genetic 
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algorithm methods. The prediction of bound conformations such as enzyme-inhibitor 
complexes, peptide-antibody complexes and even protein-protein interactions has 
shown a great success through AutoDock. Possible orientations are evaluated with 
AMBER force field model in conjunction with free energy scoring functions and a 
large set of protein-ligand complexes with known protein-ligand constants. The newest 
unreleased version 4 contains side chain flexibility. AutoDock has more informative 
web pages than its competitors; because of its free academic license[35]. 
Autodock 4.2 
 Auto Dock 4.2 uses a semi-empirical free energy force field to evaluate 
conformations during docking simulations. The force field evaluates binding in two 
steps. The ligand and protein start in an unbound conformation. In the first step, the 
intra molecular energies are estimated for the transition from these unbound states to 
the conformation of the ligand and protein in the bound state. The second step then 
evaluates the intermolecular energies of combining the ligand and protein in their 
bound conformations. The parameters are based on the amber force field[32]. 
Applications of drug design 
o Lead identification 
o Lead optimization 
o Structural elucidation by X-ray crystallography 
o Virtual screening analysis 
o Structure based drug design 
o Combinatorial library design 
o Chemical mechanistic studies 
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Fig 5: Biosynthesis of angiotensin converting enzyme 
Angiotensin converting enzyme 
Angiotensin converting enzyme is a zinc metalo-peptidase that hydrolyses 
carboxyl terminal dipeptide of many oligopeptide substrates, inclusive of angiotensin 
I (Ang I) and bradykinin. This enzyme is most commonly related with the control of 
blood pressure.[2,16] The octapeptide Angiotensin II is one of the most potent 
vasoconstrictors. ACE is widely distributed in various body tissues, in which 
predominantly present in kidney epithelium.[16] In Renin – Angiotensin Aldosterone 
system (RAS), ACE and angiotensin II are biologically active components of RAS. 
These components play a key role in maintenance of blood pressure. ACE inhibitors 
competitively inhibit the angiotensin converting enzyme which is used to treat 
hypertension, cardiac failure, diabetic nephropathy, acute myocardial infarction[39]. 
Doxorubicin induced myocardial infarction in rats 
Doxorubicin, also known as Adriamycin, is an anthracycline antibiotic, that 
was discovered from a mutated strain of Streptomyces peucetius. It has been used 
against cancer since 1960s. It is one of the most effective anticancer drugs, because of 
its cardiotoxicity doxorubicin have been reported. Therefore, chemotherapy with 
doxorubicin is limited by its cardiotoxicity. The development of cumulative dose-
dependent cardiomyopathy may occur many years after the cessation of doxorubicin 
treatment. It has been calculated that approximately 10% of patients treated with 
doxorubicin will develop cardiomyopathy and heart failure. Owing to the importance 
of doxorubicin in the chemotherapy treatment for many cancer types, strategies have 
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been tried to prevent or attenuate the side effects of doxorubicin administration, 
including the use of doxorubicin analogues, alternative drug-delivery methods, and 
iron-chelating agents. However, so far, the ability of treatments to prevent or attenuate 
doxorubicin-induced damage has been limited, and discovery of novel agents for 
reducing its side effects is still needed[40]. 
Doxorubicin consists of a naphthacene quinone nucleus and daunosamine, an 
amino sugar. Doxorubicin has both hydrophilic and hydrophobic regions, allowing it 
to bind to plasma proteins as well as cell membranes. Doxorubicin is also amphoteric; 
in having both acidic and basic functions. It is these features that make doxorubicin a 
versatile compound, allowing it to enter various cellular compartments. Doxorubicin 
can be reduced intracellularly into doxorubicinol and this metabolite also has 
biological activity. Doxorubicin can also be reduced to a semiquinone radical by many 
of the intracellular oxidoreductases. Reoxidation of this radical resulted in the 
production of reactive oxygen. Doxorubicin operates on several levels by different 
molecular mechanisms including an interaction with iron, upsetting calcium 
homeostasis, altering the activity of intracellular or intra mitochondrial oxidant 
enzymes, and binding to topoisomerases promoting their dysfunction[40].  
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REVIEW OF LITERATURE 
In silico Docking of angiotensin converting enzyme 
Muhammad and Fatima., 2015 analysed the inhibitory action of quercetin by 
computational docking studies. They have isolated quercetin from buckwheat and 
onion and used as ligand for molecular interaction. The crystallographic structure of 
molecular target angiotensin‑converting enzyme (ACE) (peptidyl‑dipeptidase A) was 
obtained from PDB database (PDB ID: 1O86). Enalapril, a ACE inhibitor was taken 
as the standard for comparative analysis. Computational docking analysis was 
performed using PyRx, AutoDock Vina option based on scoring functions. The 
quercetin showed optimum binding affinity with a molecular target 
(angiotensin‑converting‑enzyme) with the binding energy of −8.5 kcal/mol as 
compared to the standard (-7.0 kcal/mol). These results indicated that quercetin could 
be one of the potential ligands to treat hypertension, myocardial infarction, and 
congestive heart failure. 
Hafeez et al., 2014 [42] worked on molecular modelling of plant flavonoids as 
angiotensin converting enzyme (ACE) inhibitors in hypertension. In their study, 
molecular modelling results clearly demonstrated that flavonoids have a similar 
binding sites and interactions with ACE as those of the synthetic drugs and prove that 
dietary flavonoids may possess properties of blood pressure regulation. In terms of the 
mode of action, flavonoids had shown competitive type of inhibition for ACE. Thus, 
in silico study is actually an added advantage to screen the ACE inhibition and 
flavonoids may serve as useful leads for the synthesis of clinically useful 
antihypertensive drugs.  
Shafari et al., 2016 [43] investigated flavonoid rich Orthosiphon stamineous 
extract was a new candidate for ACE-I inhibition. In this study, they demonstrated the 
changes in the flavonoidal active core affects its capacity to inhibit the ACE and 
production of chelate with zn (II) ion and this interaction stabilized by other 
interactions with amino acids in the active site.   
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Synthesis of flavonoids 
Kshathriya et al., 2013 [44] designed and synthesized a class of flavonoids 
based on the backbone of 2-phenylchromen-4-one. Flavones are mainly found in 
cereals and herbs. Flavones are biologically active compounds. Therefore, number of 
synthetic methods were developed. Some of the well-known methods used for 
synthesis of flavones are Baker & Venkatraman synthesis and Claisen-Schmidt 
condensation.  
Tang et al., 2004 [45] described a novel approach to the synthesize 6-amino-7-
hydroxyflavone. Reaction in acetone 2, 4-dihydroxy-5-nitroacetophenone and benzoyl 
chloride in the presence potassium carbonate affords 3-benzoyl-7-hydroxy-6-
nitroflavone, which is cleaved in 5% ethanolic potassium hydroxide to give 1-(2,4-
dihydroxy-5-nitrophenyl)-3-phenyl-1,3-propanedione. The 1,3-diketone thus formed 
is then transformed into 7-hydroxy-6-nitroflavone, followed by reduction to afford the 
title compound.  
Patil., 2013[69] synthesized 3- benzoyl flavone 4 via modified Baker-
Venkatraman reaction. The chemical structure of the newly synthesized compound 
was confirmed by 1H NMR, MS, IR spectral data. Acute oral toxicity of the 
synthesized compound was determined as per OECD guidelines-423 and dose for 
biological activity was found to be 200 mg/ kg body weight. The compound was 
screened for anti-inflammatory (carrageenan-induced rat paw oedema model), anti-
oxidant activity (DPPH-radical scavenging model) and brine shrimp cyto-toxicity 
assay. On screening, it was found that 3-benzoyl flavone with electron donating 
substitutions has significant antioxidant potential and anti-inflammatory activity. Also 
screening of anti-cancer activity on 60 cell lines of 9 different types of cancers by NCI 
– NIH showed that compound is active against renal cancer (cell line UO-31). Results 
obtained from pharmacological screening is satisfactory as compared with 
corresponding standards used. Collectively, these results show that flavonoid with 
electron donating substitution like dimethyl amino [-N(CH3)2] group has significant 
antioxidant activity. The strong antioxidant potential could allow this flavone 
derivative to be administered for prevention of numerous free radical based diseases.  
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Huang et al.,2003[60] designed and synthesized the flavonoids of scutellaria 
baicalensis.  They successfully attained an extremely efficient route for the preparation 
of baicalein, oroxylin A, and wogonin. To our best knowledge, for total synthesis of 
these three pharmacologically diversified flavonoids, our approach is the only practical 
path featuring in beginning with a common starting material, using affordable reagents 
and proceeding under mild conditions and thus suitable for largescale pilot-plant 
synthesis. Various flavone derivatives are now being prepared in our laboratory by the 
above-mentioned methodology with a view to extensively evaluating their biological 
activities. The experimental details and biological data will be published shortly. 
In vitro angiotensin converting enzyme inhibitory activity  
Ranjini et al., 2015[80] examined aqueous extracts of Rauwolfia serpentina 
leaves and Allium sativum cloves on sheep kidney and lung ACE. In their method 
Hippuryl-Histidyl-Leucine (HHL) was used as substrate, sheep kidney and lung ACE 
activity was measured and the hippuric acid released was measured 
spectrophotometrically at 228 nm. The results of linearity of ACE activity in kidney 
and lung was established with HHL as substrate for the incubation period of 30 min at 
37°C. ACE activity was confirmed with specific ACE inhibitors like captopril, 
lisinopril and enalapril. About 25 ȝl of R. serpentina leaf extract reduced ACE activity 
by 68% and 57% in kidney and lung respectively and 25 ȝl of A. sativum cloves extract 
reduced ACE activity by 50% and 60% in kidney and lung respectively. The 
significant inhibition of kidney and lung ACE activity by these two plant products 
suggests their possible role in controlling blood pressure as a mode of treatment for 
cardiovascular diseases, when used as supplement medicine. 
Balasuriya et al., 2011 extracted flavonoids from the apple skin and the major 
constituents of the extract and some of the selected metabolites were assessed for in 
vitro ACE inhibitory property. All the flavonoids tested have a potential to inhibit ACE 
in vitro and inhibitory property varies according to the type of sugar moiety attached 
at the C3 position. 
Deo et al., 2016 reported the potential of selected Australian medicinal plant 
extracts to inhibit protein glycation and enzymes related to hyperglycaemia and 
37 
 
hypertension. Extracts of the leaves of Petalostigma banksii and P. pubescens showed 
the strongest inhibition of α-amylase with IC50 values of 166.50 ± 5.50 ȝg/mL and 
160.20 ± 27.92 ȝg/mL, respectively. The P. pubescens leaf extract was also the 
strongest inhibitor of α-glucosidase with an IC50 of 167.83 ± 23.82 ȝg/mL. Testing 
for the antiglycation potential of the extracts, measured as inhibition of formation of 
protein-bound fluorescent AGEs, showed that P. banksii root and fruit extracts had 
IC50 values of 34.49 ± 4.31 ȝg/mL and 47.72 ± 1.65 ȝg/mL, respectively, which were 
significantly lower (p < 0.05) than other extracts. The inhibitory effect on α-amylase, 
α-glucosidase and the antiglycation potential of the extracts did not correlate with the 
total phenolic, total flavonoid, FRAP or DPPH. For ACE inhibition, IC50 values 
ranged between 266.27 ± 6.91 to 695.17 ± 15.38 ȝg/mL. 
Doxorubicin induced myocardial infarction 
Chen et al., 2016[55] studied the protective effects of water and ethanol extracts 
of three varieties of yam, against DOX-induced cardiotoxicity in experimental mice. 
DOX treatment led to significant decreases in the ratio of heart weight to body weight 
and heart rate, and increases in blood pressure and the serum level of lactate 
dehydrogenase, a marker of cardiotoxicity, were recovered by yam extracts, especially 
in water extract. Yam extracts also decreased the cardiac levels of thiobarbituric acid 
reactive substances, reactive oxygen species, and inflammatory factors, as well as the 
expression of nuclear factor kappa B, while ethanol extracts of two species were shown 
to be more potent. Moreover, yam extracts had a role in increasing the activities of 
glutathione peroxidase and superoxide dismutase, thus improving the DOX-induced 
alterations in oxidative status in the heart tissue of DOX-treated mice. All ethanol 
extracts of yam exhibited their antiapoptotic abilities on caspase-3 activation and 
mitochondrial dysfunction. Based on these findings, it was concluded that yam has 
significant cardioprotective properties against DOX-induced damage via its multiple 
effects on antioxidant, anti-inflammatory, or antiapoptotic activities. 
Koti et al., 2012[62] explored Vedic Guard, a polyherbal formulation used in 
the treatment of various ailments, however, is not scientifically assessed for its effect 
on doxorubicin-induced cardiotoxicity. Cardiotoxicity was induced by doxorubicin. 
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Vedic guard was administered as pre-treatment for 2 weeks and then for 2 weeks 
alternated with doxorubicin. The general observations, mortality, histopathology, 
biomarker like lactate dehydrogenase, creatine phosphokinase, aspartate 
aminotransferase, alanine transaminase, electrocardiographic parameters, antioxidants 
such as glutathione, superoxide dismutase, and catalase were monitored after 3 weeks 
of last dose. The repeated administration of DXR causes cardiomyopathy associated 
with an antioxidant deficit. Pre-treatment with Vedic guard decreases serum enzymes 
levels to that of normal values. Vedic guard significantly protected the myocardium 
from the toxic effect of doxorubicin, by increasing the levels of antioxidants such as 
GSH, SOD, and CAT and decreased the elevated level of malondialdehyde. It also 
reduced the severity of cellular damage of the myocardium confirmed by 
histopathology. The results of the present study indicated cardioprotective effect of 
Vedic guard might be attributed to its antioxidant activity. 
Davey et al.,2011[83] proved the inotropic and cardioprotective effect of 
Terminalia paniculata in doxorubicin induced cardiotoxicity in rats.  Terminalia 
paniculata extract reduced mortality and mitigation of cardiac injury markers, 
improved ATPase activity and restoration of oxidant/ antioxidant status as well as 
lessening histopathological changes. The study proved that Terminalia paniculata 
improved cardiac protection against doxorubicin cardiotoxicity. 
Swami et al., 2011 studied the preventive role of curcumin against 
doxorubicin- induced myocardial toxicity in rats. The general observations, mortality, 
histopathology, biomarker enzymes like lactate dehydrogenase, creatine 
phosphokinase, biochemical parameters such as aspartate aminotransferase alanine 
aminotransferase and alkaline phosphatase, antioxidant enzymes such as glutathione, 
superoxide dismutase and catalase were monitored after three weeks of last dose. The 
repeated administration of Dox induced cardiomyopathy associated with an 
antioxidant deficit and increased level of biomarkers. Pre-treatment with the curcumin 
significantly protected myocardium from the toxic effects of Dox by reducing the 
elevated level of biomarker enzymes and biochemical parameters back to normal. 
Curcumin increased the reduced level of GSH, SOD and CAT and decreased the 
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elevated level of malondialdehyde in cardiac tissue. The biochemical and 
histopathology reports support the cardioprotective effect of curcumin which could be 
attributed to antioxidant. 
Vijay et al., 2011 examined the cardioprotective, antioxidant activities and 
phytochemical analysis of Gmelina arborea on doxorubicin induced myocardial 
necrosis on rats. Doxorubicin generates free oxygen radicals and resulted in serious 
dose-limiting cardiotoxicity. Supplementations with Gmelina arborea proved 
effective in reducing oxidative stress associated with several ailments. GA protected 
against DOX-induced MI and increased the levels of marker enzymes. The extract 
significantly inhibited glutathione (GSH) depletion in cardiac tissues. The reductions 
of cardiac activities of catalase (CAT), superoxide dismutase (SOD), glutathione 
peroxidase (GSH-Px) and glutathione reductase (GR) were significantly mitigated. 
Pre-treatment of GA significantly guarded against DOX-induced rise of serum lactate 
dehydrogenase (LDH). GA alleviated histopathological changes in rats’ hearts treated 
with DOX.  
Palani et al., 2012 examined the cardioprotective activity of ethanol extract of 
Flacourtia indica (FI) against doxorubicin (DOX)-induced myocardial infarction(MI) 
in rats. Different phytoconstituents were identified by gas chromatography, mass 
spectroscopy. DOX is a chemotherapeutic agent which produces free oxygen radicals 
that result in serious dose-limiting cardiotoxicity. The pre-treatment with test drug to 
DOX-treated rats significantly prevented the altered biochemical parameters such as 
serum marker enzymes serum glutamate-pyruvate transaminase, serum glutamate 
oxaloacetate transaminase, creatine phosphokinase, and lactate dehydrogenase, lipid 
profile such as low-density lipoprotein, very low-density lipoprotein, triglycerides, 
high-density lipoprotein, total cholesterol, and antioxidant parameters such as 
superoxide dismutase, glutathione, catalase, glutathione peroxidase, and 
malondialdehyde to near normal level. Serum urea, uric acid, and alkaline phosphate 
which are increased on DOX administration registered near normal values on pre-
treatment with FI. The data obtained suggested that the ethanol extract of FI can 
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prevent heart damage by DOX-induced MI in rats and this is likely mediated through 
its antioxidant activities. 
Thippeswamy et al., 2011 investigated the effect of the aqueous extract 
of Phyllanthus niruri against doxorubicin-induced myocardial toxicity in rats. 
Cardiotoxicity was produced by Dox administration and test drug was administered as 
pre-treatment for 2 weeks alternated with Dox for the next 2 weeks. The general 
observations, mortality, histopathology, biomarker enzymes like lactate 
dehydrogenase (LDH), creatinine phosphokinase (CPK) and alkaline phosphatase, 
diagnostic enzyme markers like aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), and antioxidants such as glutathione (GSH), superoxide 
dismutase (SOD), catalase (CAT) and malondialdehyde (MDA) were monitored after 
3 weeks of the last dose. Pre-treatment with aqueous extract of Phyllanthus niruri 
significantly protected the myocardium from the toxic effects of Dox by reducing the 
elevated level of biomarker and diagnostic enzymes like LDH, CPK, AST and ALT to 
the normal levels. Aqueous extract increased the GSH, SOD and CAT levels and 
decreased the MDA levels in cardiac tissue. Administration of Dox caused 
cardiomyopathy associated with an antioxidant deficiency. These results suggest a 
cardioprotective effect of P. niruri due to its antioxidant properties. 
Swamy et al., 2011 explored the preventive and curative role of ascorbic acid 
on doxorubicin-induced myocardial toxicity in rats. The test drug was given for 15 
days and doxorubicin administered in accumulative dose. The biochemical parameters 
such as tissue glutathione, malondialdehyde, catalase, and superoxide dismutase, and 
enzyme biomarkers such as creatine phosphokinase, lactate dehydrogenase, aspartate 
aminotransferase and alanine aminotransferase were monitored. Pre-treatment with 
ascorbic acid significantly protected the myocardium from the toxic effect of dox, by 
increasing the levels of antioxidant enzymes toward normal and decreased the levels 
of MDA, CPK, LDH, AST, and ALT as compared with dox-treated rats. Post-
treatment with ascorbic acid to dox-treated group significantly increased the levels of 
tissue GSH, SOD, CAT and significantly decreased the level of MDA as compared 
with dox-treated group. It also reduced the severity of cellular damage of the 
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myocardium as confirmed by histopathology. The restoration of the endogenous 
antioxidant system clearly depicts that ascorbic acid produced its protective effect by 
scavenging the reactive oxygen species. The results obtained in this study provided 
evidence for the usefulness of the ascorbic acid as a cardioprotective agent. 
Warpe et al., 2014 revealed the cardioprotective activity of ellagic acid on 
doxorubicin induced cardiotoxicity. Ellagic acid was administered respectively once 
daily orally for 6 weeks. On the last day of the study, blood was collected by retro-
orbital puncture and LDH and CK-MB were estimated. The animals were cannulated 
and the ECG and hemodynamic parameters were recorded. The animals were then 
sacrificed and histology of heart was performed. Doxorubicin showed cardiotoxicity 
manifested by changes in serum marker enzymes, ECG and hemodynamic parameters 
which was further confirmed by histology of heart. This doxorubicin induced changes 
were attenuated by treatment with ellagic acid. Ellagic acid treatment for 6 weeks 
protects the heart of rats in doxorubicin induced cardiotoxicity. 
Sun et al., 2013 explored the possible protective effect of isorhamnetin against 
Dox-induced cardiotoxicity and its underlying mechanisms. Rats were 
intraperitoneally (i.p.) administered with Dox to duplicate the model of Dox-induced 
chronic cardiotoxicity. Daily pre-treatment with isorhamnetin (5 mg/kg, i.p.) for 7 days 
was found to reduce Dox-induced myocardial damage significantly, including the 
decline of cardiac index, decreased in the release of serum cardiac enzymes and 
amelioration of heart vacuolation. In vitro studies on H9c2 cardiomyocytes, 
isorhamnetin was effective to reduce Dox-induced cell toxicity. A further mechanism 
study indicated that isorhamnetin pre-treatment can counteract Dox-induced oxidative 
stress and suppress the activation of mitochondrion apoptotic pathway and mitogen-
activated protein kinase pathway. Isorhamnetin also potentiated the anti-cancer 
activity of Dox in MCF-7, HepG2 and Hep2 cells. These findings indicated that 
isorhamnetin can be used as an adjuvant therapy for the long-term clinical use of Dox. 
Acker et al., 1995 investigated whether 7-monohydroxyethylrutoside (mono 
HER), a powerful antioxidative flavonoid with extremely low toxicity, can provide 
protection to an extent comparable to the clinically successful cardioxane (ICRF-187). 
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Balb/c mice of 20-25 g were equipped i.p. with a telemeter to measure ECG. They 
were given six i.v. doses of doxorubicin (4 mg kg-) at weekly intervals. ICRF-187 (50 
mg kg) or mono HER (500 mg kg'-) were administered i.p. 1 h before doxorubicin 
administration. In the 2 mono HER groups the treatment continued with either 1 or 4 
additional injections per week. A saline and mono HER treated group served as 
controls. After these 6 weeks, they were observed for another 2 weeks. At the end of 
this study (week 8) the ST interval had increased by 16.7 ± 2.7 ms in doxorubicin-
treated mice. At that time, the ST interval had increased by only 1.8 0.9 ms in ICRF-
187co-mediated mice and in mono HER co-medicated mice by only 1.7 + 0.8 and 5.1 
+ 1.7 ms (5- and 2-dayschedule, respectively, all P <0.001 relative to doxorubicin and 
not significantly different from control). The ECG of the control animals did not 
change during the entire study. The QRS complex did not change in either group. it 
can be concluded that mono HER protects against doxorubicin-induced cardiotoxicity 
and merits further evaluation in this respect. 
Kumar et al., 2016 designed to evaluate the cardioprotective potential of 
Acorus calamus on doxorubicin-induced myocardial toxicity in Albino Wistar rats 
were used in this study. DOX was administered intraperitoneally in six equal injections 
(each containing 2.5 mg/kg to a total cumulative dose of 15 mg/kg over 2 weeks to 
produce cardiotoxicity. Control and treated group animals were used for the estimation 
of lipid and cardiac biomarkers. Animals were sacrificed and heart tissue was used for 
the assay of glutathione (GSH), malondialdehyde(MDA), catalase (CAT), and 
superoxide dismutase (SOD) and also for the membrane-bound enzymes namely Na+-
K+-ATPase, Ca+2-ATPase, and Mg+2-ATPase. The remaining portion of the heart 
tissue was used for histopathological studies. Pre-treatment with drug decreases serum 
enzyme levels and lipid profiles brought to the near normal values, and it significantly 
protected the myocardium from the toxic effect of DOX, by increasing the levels of 
antioxidant enzymes such as GSH, SOD, and CAT toward normal and decreasing the 
increased level of MDA. AC (200 mg/kg) + DOX showed significant increase in Na+-
K+-ATPase and Mg+2-ATPase and decrease in Ca+2-ATPase compared to DOX-
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treated groups. The results of this study indicated that the cardioprotective effect of 
AC might be attributed to its antioxidant property.  
Razmaraii et al., 2016 determined the ability of grape seed extract as a 
powerful antioxidant in preventing adverse effect of doxorubicin (DOX) on heart 
function. Left ventricular function and hemodynamic parameters were assessed using 
echocardiography, electrocardiography and a Millar pressure catheter. 
Histopathological analysis and in vitro antitumor activity were also evaluated. DOX 
induced heart damage in rats through decreasing the left ventricular systolic and 
diastolic pressures, rate of rise/decrease of LV pressure, ejection fraction, fractional 
shortening and contractility index as demonstrated by echocardiography, 
electrocardiography and hemodynamic parameters relative to control group. Our data 
demonstrated that GSE treatment markedly attenuated DOX-induced toxicity, 
structural changes in myocardium and improved ventricular function. Additionally, 
GSE did not intervene with the antitumor effect of DOX. The results suggest that GSE 
is potentially protective against DOX-induced toxicity in rat heart and maybe increase 
therapeutic index of DOX in human cancer treatment. 
Sattar et al., 2012 investigated cardioprotective effect of Stachys schimperi 
Vatke on DOX-induced cardiotoxicity in rats. The phenolic profile of the methanol 
extract was determined qualitatively by HPLC. The methanol extract showed moderate 
protection against DOX-induced alteration in cardiac oxidative stress markers; GSH 
and MDA, and cardiac serum markers; CK-MB and LDH activities. Additionally, 
histopathological study denoted mild protection against DOX-induced cardiotoxicity. 
Kulkarni and Swamy, 2015 studied the protective and potential effect of 
gallic acid against doxorubicin (DOX) induced cardiotoxicity. Doxorubicin 
administered intraperitoneally in six equal injections to total cumulative doses of 15 
mg/kg over a period of 2 weeks to induce cardiotoxicity. The estimation of cardiac and 
lipid biomarkers of both control and treated animals were observed. In vivo antioxidant 
parameters such as glutathione, superoxide dismutase, catalase, and malondialdehyde 
were also monitored. The remaining portion of the heart tissue used for 
histopathological studies. The treatment with doxorubicin increased the levels of 
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serum cardiac and lipid biomarker which were brought down by gallic acid treatment. 
It also exhibited electrocardiographic changes such as reduced R wave and ST segment 
elevation. Histopathological study revealed that gallic acid restored the myocardial 
cells towards normal. The restoration of the endogenous antioxidant system clearly 
depicts that gallic acid have produced its protective effect by scavenging the reactive 
oxygen species. The results of this study indicated that the cardioprotective effect of 
gallic acid might be attributed to its antioxidant property. 
Karim et al., 2001 revealed the protective effects of enalapril, losartan, vitamin 
A, aspirin, melatonin and a combination of melatonin and aspirin against doxorubicin 
induced cardiotoxicity in rats. Enalapril, losartan, vitamin A, melatonin and melatonin 
+ aspirin were given for 5 days to albino rats followed by doxorubicin. Biochemical 
parameters like serum AST and blood GSH, tissue TBARS and GSH were estimated 
to assess to cardiac function. Doxorubicin treatment increased the levels of serum AST 
in rats. Pre-treatment with enalapril, losartan, vitamin A, aspirin, melatonin, and 
melatonin + aspirin decreased the levels of serum AST of the rats treated with 
doxorubicin. Doxorubicin induced fall in blood GSH, tissue GSH were reversed by 
enalapril, losartan, vitamin A, aspirin, melatonin and melatonin + aspirin. Doxorubicin 
induced elevation of TBARS in cardiac tissue was also significantly reduced by the 
above treatments. Combined administration of melatonin and aspirin may offer better 
protection as compared to melatonin alone against doxorubicin induced cardiotoxicity. 
Abirami and Kanagavalli, 2013 evaluated doxorubicin induced 
cardiotoxicity in rats using grape seed proanthocyanidin. Intraperitoneal injection of 
DOX [10mg kgˉ¹/b.wt] administrated once a day for 15 days was revealed by elevated 
serum creatine phoshokinase [CPK], lactate dehydrogenase [LDH], aspartate 
transaminase [ASP], alanine transaminase [ALT], HDL cholesterol and triglycerides 
in comparison of control and associated with increasing levels of myocardial 
malondialdehyde [MDA] with simultaneously decrease in the level of glutathione 
peroxidase [Gpx], glutathione-S transferase [GST] and glutathione reductase [GR] 
daily oral administration of aqueous suspension of GSP seeds extract. The study 
showed that GSP seeds possess antioxidant and cardioprotective effect. 
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OBJECTIVE OF THE STUDY 
Myocardial infarction (MI) is a leading cause of mortality, it is the irreversible 
necrosis of heart muscles secondary to prolonged ischemia. This usually results from 
an imbalance of oxygen supply and demand. The incidence of MI is rising in young 
individuals owing to change in lifestyle pattern, eating habits, more stress and 
workload. Incidence remained highest in Males as compared to females. Highly 
associated risk factor in young myocardial infarction patients are dyslipidaemia, 
smoking, diabetes, hypertension.  
Angiotensin Converting Enzyme (ACE), the central component of the renin -
angiotensin system (RAS) controls the blood pressure by regulating the volume of 
fluids in the body. It converts the hormone angiotensin-I to the angiotensin- II. 
Therefore, ACE indirectly increases blood pressure by causing blood vessels to 
constrict. 
The inhibition of ACE is considered as one of the most effective therapeutic 
strategy for the treatment of myocardial infarction. Enzyme inhibitors are used as 
potent therapeutic agents for the treatment of various diseases. More than 100 drugs 
are used worldwide as enzyme inhibitors.    ACE inhibitors such as captopril, enalapril, 
fosinopril and Ramipril are currently available in the market. 
Flavonoids are fairly versatile compounds and are easy to synthesize. They are 
associated with a wide range of pharmacological actions including antioxidant, 
antimicrobial, anticancer, anti-inflammatory activities and also possesses ACE 
inhibitory activity.  
Doxorubicin is a powerful, well-established and highly efficacious drug in 
many kinds of cancers. But its clinical usefulness is still restricted due to its specific 
toxicities to cardiac tissues. Congestive heartfailure, cardiomayopathy and 
electrocardiographic changes were demonstrated after cumulative doxorubicin 
administration. Myocardial infarction produced by doxorubicin through different 
mechanisms like lipid peroxidation, mitochondrial DNA damage, myocardial injury, 
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contractile dysfunction, apoptosis. The flavonoids having an ability to inhibit these 
mechanisms.  
The present study mainly focuses on the design and synthesis of certain 
flavonoid derivatives in order to explore the extent of their cardioprotective activity 
and also identify the conformations of ligands in the active site of protein and to predict 
the affinity of the ligands towards the protein. Drug discovery tools have been utilized 
in designing new chemical entities which are safe and effective without consuming 
much of the research hours. 
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PLAN OF WORK 
✓ STEP I 
Designing and determination of ACE inhibitory activity of 50 flavonoid 
compounds   
✓ STEP II 
Determination of bioactivity scores by using molinspiration software 
✓ STEP III 
To carry out the molecular docking studies using Autodock 4.2 based on the 
bioactive score.    
✓ STEP IV 
Evaluation of toxicity using the software T.E.S.T   
✓ STEP V 
Selection of five flavonoids based on their docking score and toxicity values   
✓ STEP VI 
Synthesis, purification and spectral analysis of 5 flavonoids 
✓ STEP VII  
In vitro screening of five synthesized flavonoids for ACE inhibitory activity 
✓ STEP VIII 
Acute toxicity study of two selected synthesized flavonoids based on their in 
vitro results  
✓ STEP IX 
In vivo screening of the two flavonoids by doxorubicin induced myocardial 
infarction in rats  
✓ STEP X 
Euthanised and collection of blood by retro-orbital plexus puncture method 
for biochemical estimations  
✓ STEP XI 
Dissection and preparation of tissue homogenate using heart for biochemical 
estimations  
✓ STEP XII 
Section of the heart tissue used for histopathology 
✓ STEPXIII 
Tabulation, compilation of results and statistical analysis of data obtained  
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MATERIALS AND METHODS 
EVALUATION OF DRUG LIKENESS PROPERTIES 
 The pharmacologically active substituents are characterized by calculating 
steric, hydrophobic, electronic, and hydrogen bonding properties as well as by the 
drug-likeness score. The theory of drug-likeness score helps to optimize 
pharmaceutical and pharmacokinetic properties, for example, chemical stability, 
solubility, distribution profile and bioavailability. The molecular descriptors have 
developed as rationally predictive and informative, for example, the Lipinski's Rule-
of-Five. The better oral absorption of the ligands and drug likeness scores are 
constructed by getting information about the solubility, diffusion, Log P, molecular 
weight etc. Molinspiration software is used to evaluate the Lipinski’s rule of five. 
 Lipinski’s rule of five calculations 
1.  Open the molinspiration home page. 
2.  For calculating using molinspiration it requires JAVA in the computer. 
3.  Click calculation of molecular properties of drug likeness 
4.  Draw the structure of flavonoids in the active window. 
5.  Click and calculate properties. 
6.  Save the properties. 
Evaluation of ADMET properties 
 The ADMET studies were performed using Accerlys Accord for excel. From 
this absorption, distribution, metabolism, of the selected ligands was evaluated. The 
2D structure was directly introduced into Accord for excel to carry out ADMET 
screening by using ChemSketch software. The data for descriptors are blood brain 
barrier (BBB), plasma protein binding, aqueous solubility and hepatotoxicity. After 
loading the structure through the function model various descriptors are tabulated. 
IN SILICO DOCKING AND BINDING INTERACTION STUDIES 
SOFTWARES AND DATA BASES USED 
➢ Accerlys discovery studio viewer 4.0.1 
➢ Molinspiration 
➢ RCSB protein data bank 
➢ OnlineSMILES translator 
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➢ MGL tools- 
▪ AutoDock 4.2 
▪ Python 2.7 molecule viewer 1.5.6 
▪ Vision 1.5.6 
▪ Cygwin 64 
➢ ChemSketch 
➢ T.E.S.T version 4.2.1 
➢ MEDCHEM designer 
In silico docking study on angiotensin converting enzyme using AutoDock 4.2 
STEP I:  
Ligand file format conversion 
➢ Flavonoid structures are drawn in CHEMSKETCH.  
➢ ToolsgenerateSMILES notation 
➢ Copy the smile notation and upload the smiles in online smile translator- 
cactus.nci.nih.gov/services/translate 
➢ By choosing the required file format and save the file as pdb format 
STEP II:  
Protein structure refinement 
Angiotensin Converting Enzyme (PDB ID:1086) download from RCSB (Research Co-
laboratory for Structural Bioinformatics) Protein Data Bank and the protein should be 
refined before use for docking.  
➢ Open Accelrys discovery studio viewer  
➢ FileopenRCSBPDB file 
➢ View hierarchyclick water molecules select all water moleculescut 
➢ Select ligand, which is unnecessary and cut  
➢ Save the molecule in a desired location 
STEP III:  
Docking with AutoDock 4.2 
➢ Open the saved refined protein from the location as in pdb format 
➢ Preparation of target and ligand in AUTODOCK 4.2 
STEP IV:  
Preparation of protein 
➢ AUTODOCK 4.2  File Read molecule Choose refined enzyme file 
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Elimination of water molecule carried out by; 
➢ Select Select from string Residue (*HOH*)  Add Dismiss 
➢ Edit Hydrogen Add Polar only Ok 
➢ Editcharges Add kollmann charges Ok 
➢ Filesave Write pdb BrowseSave Ok 
➢ Edit Delete all molecules Continue 
STEP V:  
Preparation of ligand 
➢ Ligandinputopen 
➢ Ligandtorsion treedetect root 
➢ Ligand torsion treeshow root expansion 
➢ Ligand torsion treechoose torsionsdone 
➢ Ligand torsion treeset number of torsionsdismiss 
➢ Ligand torsion treehide root expansion 
➢ Ligand torsion treeshow/hide root marker 
➢ Ligandoutput save as pdbqt file 
➢ Editdeletedelete all molecules continue 
Conversion of pdb files of protein in to pdbqt file  
➢ Grid Macromolecule Open Save as pdbqt 
AutoGrid calculation and creating “gpf” file 
➢ Gridset map types open ligand 
➢ Gridgrid boxset 60 points in XYZ 
➢ Fileclose saving current 
➢ Gridoutputsave as GPF 
➢ Editdeletedelete all moleculescontinue 
AUTODOCK calculation and creating ‘dpf’ file 
➢ Dockingmacromoleculeset rigid file name open 
➢ Dockingligandopenaccept 
➢ Dockingsearch parametersgenetic algorithaccept 
➢ Dockingdocking parametersaccept 
➢ Dockingoutputlamarckian genetic algorithmsave as dpf 
Programming of ‘Auto Grid’ and ‘Auto Dock’ execution 
Open Cygwin and type as given below: 
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❖ cd C: 
❖ cd cygwin 
❖ cd usr 
❖ cd local 
❖ cd bin 
❖ ls 
program should list out the pdb, pdbqt, gpf and dpf files of an enzyme and ligand 
molecule. 
Then type as: 
❖ ./autogrid4.exe<space>–p<space>ligand.gpf-l<space> ligand.glg 
If a ligand gets into the spacing of the grid, then the execution of this command will 
be;  
✓ ‘Successful completion’ 
Then type as:  
❖ ./autodock4.exe<space> –p<space> ligand.dpf-l<space> ligand.dlg 
If the ligand binds to the amino acids through 10 different conformations, then the 
execution of this command will be; 
✓ Successful completion’ 
STEP IV:  
Viewing docking results  
Reading the docking log file. dlg 
➢ Toggle the AutoDock Tools button 
➢ Analyse  Docking 
➢ Analyse  Conformations  Load 
➢ Double click on the conformation for to view it 
Visualizing docked conformations 
➢ Analyse  Dockings  Play 
➢ Load dlg file  
➢ Choose the suitable conformations 
➢ Analyse  Docking  Show Interactions 
Obtaining snap shots of docked pose  
➢ File  Read Molecule  
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➢ Analyse Dockings  Open dlg file  
➢ Analyse Macromolecule  Choose pdbqt file. 
➢ Analyse Conformations  Load  
➢ Double click the desired conformation 
➢ Analyse  Docking  Show Interactions 
 Proteins and ligand interaction will be displayed. Zoom it and increase the 
contrast by holding right key and ctrl. Rapid energy evaluation was attained by pre-
calculating the atomic resemblance potentials for each atom in the selected flavonoids. 
In the AutoGrid process, the target was enclosed on a three-dimensional grid point and 
the energy of interface of each atom in the flavonoids were encountered. The following 
docking factors were chosen for the Lamarckian genetic algorithm as follows: 
population size of 150 individuals, 2.5 million energy evaluations, maximum of 27000 
generations, and number of top individuals to automatically survive to next generation 
of 1, mutation rate of 0.02, crossover rate of 0.8, 10 docking runs, and random initial 
positions and conformations. The probability of performing local search on a single 
compound in the population was set to 0.06. AutoDock was run various times to obtain 
various docked conformations, and used to calculate the predicted binding energy46. 
CHEMICALS AND REAGENTS 
 2-Hydroxy acetophenone, dry acetone, anhydrous potassium carbonate, dilute 
hydrochloric acid, 2-ethoxy benzoic acid, 2,4-dichloro benzoic acid 2-chlorobenzoic 
acid, 4-chlorobenzoic acid, 2-chloro 5-nitro benzoic acid were procured from Sigma 
Aldrich. Sheep lung tissue was purchased from slaughter house at Coimbatore. 
Hippuryl- L- Histidyl - L- Leucine (HHL) (Sigma Aldrich), enalapril 
(Dr.Reddys,Hyderabad), doxorubicin (Pfizer New York), borate buffer pH-8.3, bovine 
serum albumin (Himedia), alkaline copper sulphate, Folin-Ciocalteau reagent, HEPES 
buffer, cyanuric chloride, 1 4-dioxan, EDTA, doxorubicin, enalapril, alkaline copper 
solution, Tris- HCl buffer, TCA-TBA-HCl reagent, Sodium azide, phenazonium 
methosulphate, glutathione, Ellman’s reagent, all serum parameter kits are procured 
from agappe diagnostics, Kerala.   
INSTRUMENTS / EQUIPMENTS USED 
 Semi auto-analyzer (Agappe Diagnostics Ltd, Mumbai), Centrifuge (Remi 
Instruments Ltd., Kolkata), UV- Visible Spectrophotometer (JASCO V-630 
spectrophotometer), MR-VIS- visual melting range apparatus. 
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SYNTHESIS OF FLAVONOIDS 
 To a stirred solution of O-hydroxy acetophenone (0.3moles) in dry acetone and 
anhydrous potassium carbonate was added and stirred at room temperature for 10min. 
The substituted benzoyl chloride (0.9moles) added in small portion to the reaction 
mixture and stirred for 30min. The reaction mixture was then refluxed for 24hrs.The 
solvent was removed by distillation under reduced pressure and the resultant solution 
was acidified with dilute hydrochloric acid. The product thus obtained was filtered, 
dried and recrystallized from ethanol13.     
Table 1: IUPAC NAMES OF THE SYNTHESIZED FLAVONOIDS 
 
COMPOUNDS 
 
IUPAC NAMES 
F1 3-(2-ethoxy benzoyl)-2-(2-ethoxy phenyl)-4H-chromen-4-one 
F2 3-(2,4-dichloro benzoyl)-2-(2,4-dichloro phenyl)-4H-chromen-4-one 
F3 3-(2-chloro benzoyl)-2-(2-chloro phenyl)-4H-chromen-4-one 
F4 3-(4-chloro benzoyl)-2-(4-chloro phenyl)-4H-chromen-4-one 
F5 3-(2-chloro-5-nitro benzoyl)-2-(2-chloro-5-nitro phenyl)-4H-chromen-4-one 
 
Table 2: PHYSICAL DATA OF SYNTHESIZED FLAVONOIDS 
 
COMPOUNDS 
MOLECULAR 
FORMULA 
MOLECULAR 
WEIGHT 
MELTING 
POINT 
F1 C26H22O5 414.44 150.5°C 
F2 C22H10Cl4O3 464.12 210.5°C 
F3 C22H12Cl2O3 395.23 113.5°C 
F4 C22H12Cl2O3 395.23 235.5°C 
F5 C22H10Cl2N2O7 485.23 123.5°C 
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Fig 6: Scheme for the synthesis of flavonoids 
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DETERMINATION OF MELTING POINT 
The melting point of the synthesized compounds (F1-F5) was determined by using 
open capillary tube using MR-VIS visual melting range apparatus.  
IN VITRO ANGIOTENSIN CONVERTING ENZYME INHITORY ASSAY 
Isolation of angiotensin converting enzyme from sheep lung extract 
Sheep lung was collected from slaughter house and one gram of sheep lung 
tissue was sliced and homogenised in 10ml of the ice cold 100Mm borate buffer 
(pH8.3) containing 50mM KCl using a homogeniser at 4°C. the homogenate was 
centrifuged at 8000g at 4°C for half an hour, and the supernatant was collected. 
Remove, if any impurities present and stored at 4°C. this supernatant was used as the 
source of ACE14. 
Estimation of protein content by Lowry method 
Different dilutions of Bovine serum albumin (1.2-1µg/ml) were prepared from 
stock BSA solution (1mg/ml) in a test tube. The final volume in each test tube was 
adjusted to 5ml with distilled water. From these dilutions, pipette out 0.2ml protein 
COMPOUND CODE R1 R2 R3 
F1 Cl H H 
F2 H Cl H 
F3 OC2H5 H H 
F4 Cl Cl H 
F5 Cl H NO2 
55 
 
solution to different test tubes and add 2ml of alkaline copper sulphate reagent 
(analytical reagent) and mix well. The solution was incubated for 10min at room 
temperature. Then add 0.2ml of Folin Ciocalteau solution to each test tube and 
incubated for 30min. The colorimeter was set to zero with blank and optical density 
was measured at 450nm. Plot the absorbance against protein concentration to get a 
standard calibration curve. Check the concentration of unknown from the standard 
curve. 
Estimation of ace from sheep lung extract 
ACE inhibitory was measured by using Hippuryl-L-histidyl-leucine (HHL) as 
substrate. This reaction mixture contained 0.2ml of 5mM HHL prepared in 200mM 
borate buffer (pH8.3) with 1000 mM KCl. The reaction was initiated by the addition 
of different concentration of lung extract and then incubated at 37°C for 30min. the 
reaction was stopped by the addition of 2ml of HEPES buffer and 1ml of 136mM 
cyanuric chloride in 1,4-dioxan and yellow colour was developed was measured at 450 
nm. Various concentration of hippuric acid (which is formed by the reaction of ACE 
on HHL) were used for the preparation of standard graph.  
In vitro angiotensin converting enzyme inhibitory activity 
Colorimetric method 
The reaction mixture contained 5mM HHL prepared in 200mM Borate buffer (Ph8.3), 
containing 1000mM KCl 10µl of different concentration of unknown drug sample (50-
800µg), lung extract (50µl) and distilled water in a volume of 1ml. The reaction 
mixtures were incubated at 37°c for 30min. the reaction was stopped by adding 2ml of 
HEPES buffer (pH9), which contain 2.5mM EDTA. Finally add 1ml of 136mM 
cyanuric chloride in 1,4-dioxan was added to the reaction mixture and shake 
vigorously for 15sec. The absorbance of yellow colour developed was measured at 
405nm. Enalapril was used as the standard drug for comparison with the assay system. 
(Rangini et al.,2015) % ACE inhibition = ሺAͲ −  AͳሻAͲ × ૚૙૙ 
A0= Absorbance of the control 
           A1= Absorbance of the standard/compounds 
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EXPERIMENTAL ANIMALS 
Healthy male Wistar rats weighing 220g±20%, procured from Kerala 
Veterinary and Animal Science University, Thrissur. The study protocol was approved 
by the Institutional Animal Ethical Committee and all procedures were performed in 
accordance with the recommendations for the proper care and use of laboratory 
animals48.  
Housing and feeding conditions 
The animals were kept in cages under ambient temperature (22 ± 3°C) with 12 h 
light/dark cycle. They were fed with standard rat laboratory diet water ad libitum. 
 
ACUTE TOXICITY STUDY OF FLAVONOIDS 
Acute oral toxicity testing was carried out in accordance with the OECD guideline 420 
Acute Oral Toxicity – Fixed Dose Procedure method (OECD, 2002).  
Procedure  
The acute toxicity study was done by two steps - sighting study and main study. 
The purpose of the sighting study is to allow selection of the appropriate starting dose 
for the main study. Healthy adult female (generally slightly more sensitive than male) 
Wistar rats weighing between 220±20%g body weight was procured and kept in cages 
under ambient temperature (22±3°C) with 12 h light/dark cycle. The animals were 
randomly selected, marked and kept in their cages for 5 days prior to dosing for 
acclimatization to laboratory conditions. The animals were fasted over-night and were 
provided with water ad libitum. The synthesized test compounds (flavonoids) was 
suspended in 0.5% CMC. Totally 18 animals were used for this study. Sighting study 
was conducted for two compounds at dose levels of 5, 50, 300 and 2000 mg/kg body 
weight using 8 animals and if the animal dosed with 2000 mg/kg b.w. survived without 
any toxic manifestations during the sighting study and the same dose was selected for 
the main study. The main study was conducted for 2 compounds at dose of 2000 mg/kg 
body weight using 10 animals. After the administration of the flavonoids, food was 
withheld for further 3-4 hours.  
Animals were observed individually at least once during the first 30 min after 
dosing, periodically during the first 24h (with special attention during the first 4 h) and 
daily thereafter for a period of 14 days. Once daily cage side observations included 
changes in skin and fur, eyes and mucous membrane (nasal), and also respiratory rate, 
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circulatory (heart rate and blood pressure), autonomic (salivation, lacrimation, 
perspiration, piloerection, urinary incontinence and defecation) and central nervous 
system (drowsiness, gait, tremors and convulsions) changes. 
Table 4: Design of acute toxicity studies 
Study involved Dose (mg/kg) No. of animals 
       Sighting study 
5 2 
50 2 
300 2 
2000 2 
Main study 2000 10 
 
IN VIVO DOXORUBICIN- INDUCED MYOCARDIAL INFARCTION 
Animals were divided into 5 groups of 8 animals each. The values for control 
and negative control group (doxorubicin 10 mg/kg i.p) were taken from archives based 
on the recommendations of CPCSEA-IAEC and denoted as group I and II respectively.  
Group III animals received flavonoid I- low dose (100 mg/kg) and doxorubicin 10 
mg/kg i.p on 26th day. Group IV, flavonoid I-high dose (200 mg/kg) and doxorubicin 
10 mg/kg ip on 26th day. Group V served as flavonoid II- low dose (100 mg/kg) and 
doxorubicin 10 mg/kg i.p on 26th day. Group VI, flavonoid II-high dose (200 mg/kg) 
and doxorubicin 10 mg/kg i.p on 26th day. Group VII animals received Enalapril (10 
mg/kg) as the standard and doxorubicin 10 mg/kg i.p on 26th day48. 
Dissection and homogenisation 
On 28th day of the treatment i.e., 48 hours after doxorubicin administration, 
animals were anaesthetized with diethyl ether. The blood was collected through retro-
orbital plexus method and the serum was separated for biochemical estimations. The 
rats were sacrificed by euthanasia and heart was separated immediately, weighed, 
immersed in saline and dissected for histopathological examination48. 
Serum biochemical parameters  
The following are the biochemical parameters used CK-MB, LDH, TROPONIN-I, 
SGPT/ALT, SGOT/AST, ALP, triglycerides, total cholesterol, HDL, LDL 
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CK-MB 
Principle: The procedure involves measurement of CK activity in the presence of an 
antibody to CK-M monomer. This antibody completely inhibits the activity of CK-
MM and half of the activity of CK-MB, while not affecting the B subunit activity of 
CK-MB and CK-BB. Then we use CK method to quantitatively determine CK-B 
activity. The CK-MB activity is obtained by multiplying the CK-B activity by two.  
Procedure: Mix the 4 volumes of Reagent 1(R1: imidazole-125mmol/l, D- glucose- 
25mmol/l, N-Acetyl-L-Cysteine- 25mmol/l, Magnesium acetate- 12.5mmol/l, NADP- 
2.52mmol/l, EDTA- 2.02mmol/l, Hexokinase >6800 U/L, Anti human polyclonal CK-
M antibody (sheep) sufficient to inhibit up to 2000U/L of CK-MM) with 1 volume of 
reagent 2 (R2: Creatine phosphate-250mmol/l, ADP-15.2mmol/l, AMP-25mmol/l, 
Diadenosine phosphate- 103mmol/l, G-6-PDH >8800 U/L)65 
LDH 
Principle: Pyruvate is reacted with NADH and one molecule of hydrogen in the 
presence of lactate dehydrogenase gives L- Lactate and NAD+   
Procedure: Mix 4 volume of Reagent1 (R1: Tris buffer -80mmol/L, Pyruvate-
1.6mmol/L) with 1 volume of reagent 2(R2: NADH-240mmol/L)66  
Troponin I 
principle: The HeartScan One Step Troponin I Card Test (Serum/Plasma) is a 
qualitative, membrane based immunoassay for the detection of troponin I in serum or 
plasma. The membrane is pre-coated with capture reagent on the test line region of the 
test. During testing, the serum or plasma specimen reacts with the particle coated with 
anti-troponin I antibodies. The mixture migrates upward on the membrane 
chromatographically by capillary action to react with capture reagent on the membrane 
and generates a coloured line. The presence of this coloured line in the test line region 
indicates a positive result, while its absence indicates a negative result. To serve as a 
procedural control, a coloured line will always appear in the control line region 
indicating that proper volume of specimen has been added and membrane wicking has 
occurred.  
Procedure:  
• Bring the pouch to room temperature before opening it. Remove the test device 
from the sealed pouch and use it as soon as possible. Best results will be 
obtained if the test is performed immediately after opening the foil pouch.  
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• Add 2 drops of serum in to the sample window. 
• Wait for coloured lines to appear. Read results at 10 minutes. Do not interpret 
results after 20 minutes68.  
SGPT 
Principle: L-alanine reacts with alpha- ketoglutarate in the presence of ALT gives 
pyruvate and L-glutamate. Pyruvate reacts with NADH and one molecule of hydrogen 
ion in the presence of lactate dehydrogenase gives L-lactate and NAD+  
Procedure: Mix 4 volume of Reagent 1 (R1: Tris buffer-110mmol/l, L-Alanine-
600mmol/L, LDH >1500U/L) with 1 volume of Reagent 2 (R2: Alpha-Ketoglutarate-
16mmol/L, NADH-0.24mmol/L)69 
SGOT 
Principle: L-Aspartate reacts with alpha- ketoglutarate in the presence of AST gives 
Oxaloacetate and L-Glutamate. Oxaloacetate reacts with NADH and one molecule of 
hydrogen ion gives L-Malate and NAD+  
Procedure: Mix 4 volume of Reagent 1(R1: Tris Buffer-88mmol/L, L-Aspartate-
260mmol/L, LDH >1500 U/L, MDH >900 U/L) with 1volume of Reagent 2 (R2: 
alpha-ketoglutarate-12mmol/L, NADH-0.24mmol/L)70 
ALP 
Principle: Para-nitrophenyl phosphate reacts with one molecule of water in the 
presence of ALP gives Para-nitrophenol and inorganic phosphate  
Procedure: Mix 4 volume of reagent 1 (R1: Diethanolamine buffer- 125mmol/L, 
Magnesium chloride-0.625mmol/L,) with 1 volume of Reagent 2 (R2: P-Nitro phenyl 
phosphate-50mmol/L)71 
Triglycerides  
Principle: Enzymatic determination of triglycerides;  
• TGL reacting with water in the presence of lipoprotein lipase to gives Glycerol 
and Fatty acid.  
• Glycerol is reacting with ATP in the presence of glycerol kinase to gives 
Glycerol -3- phosphate and ADP. 
• Glycerol -3- phosphate reacting with 2 molecules of oxygen in the presence of 
Glycerol -3- phosphate oxidase gives dihydroxyacetophenone and 1 molecule 
of hydrogen peroxide. 
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• 2 molecules of hydrogen peroxide reacting with 4- aminoantipyrine and TOPS 
gives violet coloured complex. 
Procedure: Mix the triglyceride reagent (pipes buffer-5mmol/L, TOPS-
5.3MMOL/L, Potassium ferrocyanate-10mmol/L, Magnsium salt- 17mmol, 4- 
aminoantipyrine-0.8mmol/L, ATP-3.15mmol/L, lipoprotein lipase >1800 U/L, 
Glycerol-3-phosphate oxidase >3500 U/L, Peroxidase >450) with triglycerides 
standard concentration- 200mg/dL71  
HDL 
Principle: The reaction between cholesterol other than HDL and the enzyme for 
cholesterol assay is suppressed by the electrostatic interaction between polyanions and 
cationic substances. Hydrogen peroxide is formed by the free cholesterol in HDL by 
cholesterol oxidase. Oxidative condensation of EMSE and 4-AA is caused by 
hydrogen peroxide in the presence of peroxidase, and the absorbance of the resulting 
red- purple quinone is measured to obtain the cholesterol value in HDL. HDL in the 
presence of polyanions and cationic substances suppress the reaction with enzyme. 
HDL (cholesterol esters) reacts with one water molecule in the presence of cholesterol 
esterase gives HDL (free cholesterol) and fatty acids. 
HDL (free cholesterol) reacts with two molecules of oxygen and one molecule of 
hydrogen ion in the presence of cholesterol oxidase gives cholestenone and hydrogen 
peroxide. Two molecules of hydrogen peroxide react with 4-AA, EMSE, three 
molecules of hydrogen and one molecule of oxygen in the presence of peroxidase gives 
violet quinone and five molecules of water.  
Procedure: Mix the reagent-1 (R1: N-ethyl-N-(3-methylphenyl)-N- 
succinylehyenediame (EMSE) and reagent-2 (R2: cholesterol oxidase 4-
aminoantipyrin(4-AA)72 
LDL  
Principle: This assay method uses a surfactant for selectively solubilizing LDL alone 
in the cholesterol assay system that employs cholesterol esterase and cholesterol 
oxidase. It passes the ester cholesterol and free cholesterol contained in the LDL to the 
cholesterol reaction system to determine LDL cholesterol. The enzyme reactions to 
other, non-LDL lipoproteins (HDL, VLDL, chilomicrons) are inhibited by the 
surfactant and by the sugar compounds. These lipoproteins are therefore not passed to 
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the cholesterol reaction system and consequently remain in the reaction liquid as 
lipoproteins.  
Procedure: Mix the reagent-1(R1: HSDA-1mmol/L, good’s buffer) and reagent-2 
(cholesterol esterase- 2.0U/L, cholesterol oxidase- 1.0mmol/L, 4-Aminoantipyrin-
2.5mmol/L and good’s buffer)73 
Preparation of tissue homogenates 
The heart tissue was removed and washed immediately with ice-cold saline to remove 
blood. A 10% w/v heart tissue homogenate was prepared in ice-cold potassium 
phosphate buffer (100mM, pH 7.4) followed by centrifugation at 5000g for 10 min. 
the resulting supernatant was used for the estimation of biochemical parameters77.  
Biochemical parameters for heart tissue homogenate 
• Estimation of total protein content 
Determination of enzymatic antioxidants 
• Assay of catalase 
• Estimation of glutathione peroxidase (GPx) 
• Assay of superoxide dismutase (SOD) 
• Estimation of glutathione reductase (GSSH) 
Determination of non-enzymatic antioxidants 
• Estimation of reduced glutathione (GSH) 
Estimation of malondialdehyde (MDA) 
Estimation of total protein content 
To 0.1ml of heart tissue homogenate, 4.0 ml of alkaline copper solution was 
added and allowed to stand for 10 min. Then, 0.4 ml of phenol reagent was added very 
rapidly and mixed quickly and incubated in room temperature for 30 min for colour 
development. Reading was taken against blank prepared with distilled water at 610 nm 
in UV-visible spectrophotometer. The protein content was calculated from standard 
curve prepared with bovine serum albumin and results were expressed as µg/mg heart 
tissue79. 
Determination of enzymatic antioxidants 
Assay of catalase 
The reaction mixture contained 2.0 ml of homogenate and 1.0 ml of 30 mM 
hydrogen peroxide (in 50 mM phosphate buffer, pH 7.0). a system devoid of the 
substrate (hydrogen peroxide) served as a control. Reaction was started by the addition 
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of the substrate and decrease in absorbance mentioned at 240 nm for 30 seconds at 
25°C. The difference in absorbance per unit time was expressed as the activity and 
three parallel experiments were conducted. One unit is defined as the amount of 
enzyme required to decompose 1.0 M of hydrogen peroxide per minute at pH 7.0 and 
25°C81. 
Estimation of glutathione peroxidase (GPx) 
The reaction mixture consists of 0.2 ml of 0.4 M Tris buffer, 0.1 ml of 1.0 mM 
sodium azide, 0.1 ml of 0.042% hydrogen peroxide, 0.2 ml of 200 mM glutathione and 
0.2 ml of heart tissue homogenate supernatant incubated at 37°C for 10 min. The 
reaction was arrested by the addition 0.1 ml of 10% TCA and the absorbance was taken 
at 340 nm. Activity was expressed as nmoles/min/mg heart protein82. 
Assay of superoxide dismutase (SOD) 
The assay mixture contained 1.2 ml of sodium pyrophosphate buffer (0.052 M, pH 
8.3), 0.1 ml of 186 µM Phenazonium methosulphate (PMS), 0.3 ml of 300 µM nitro 
blue tetrazolium chloride (NBT), 0.2 ml of 780 µM NADH, 1.0 ml of homogenate and 
distilled water to a final volume of 3.0 ml. reaction was started by the addition of 
NADH and incubated at 30°C for 1 min. The reaction was stopped by the addition of 
1.0 ml of glacial acetic acid and the mixture was stirred vigorously. 4.0 ml of n-butanol 
was added to the mixture and shaken well. The mixture was allowed to stand for 10 
min, centrifuged, the butanol layer was taken out and absorbance was measured at 560 
nm against a butanol blank. A system devoid of enzyme served as the control and three 
parallel experiments were conducted83.  
Estimation of glutathione reductase (GSSH) 
The enzyme activity was determined spectrophotometrically by the decrease in 
absorbance of NADPH at 340 nm. The reaction mixture contained 2.1 ml of 0.25 mM 
potassium phosphate buffer pH 7.6, 0.1 ml of 0.001 M NADPH, 0.2 ml of 0.0165 M 
oxidized glutathione and 0.1 ml of bovine serum albumin (10 mg/ml). The reaction 
was started by the addition of 0.02 ml of heart tissue homogenate with mixing and the 
decrease in absorbance at 340 nm was measured for 3 min against a blank. Glutathione 
reductase activity was expressed as nmoles/min/mg heart protein at 30°C84.  
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Determination of non-enzymatic antioxidants 
Estimation of reduced glutathione (GSH) 
Heart was homogenized in 10% w/v cold 20mM EDTA solution on ice. After 
deproteinization with 5% TCA, an aliquot of the supernatant was allowed to react with 
150 µM DTNB. The product was detected and quantified spectrophotometrically at 
416 nm. Pure GSH was used as standard for establishing the calibration curve and 
three parallel experiments were conducted85. 
Estimation of Lipid peroxidation indices 
Estimation of malondialdehyde (MDA) 
One ml of the heart tissue homogenate was combined with 2 ml of TCA-TBA-HCl 
reagent (15% trichloro acetic acid (TCA) and 0.375% thiobarbituric acid (TBA) in 
0.25 N HCl) and boiled for 15 min. precipitate was removed after cooling by 
centrifugation at 1000g for 10 min and absorbance of the sample was read at 535 nm 
against a blank without tissue homogenate. The levels of MDA were calculated using 
extinction coefficient calculation. The values are expressed as n moles/min/mg heart 
tissue80. 
Histopathological studies 
After draining the blood heart samples were excised, washed with normal saline and 
processed with separately for histopathological observations. The portion of the heart 
were incised and immersed in 10% formalin for 48 hrs for histopathological 
examination. Paraffin sections were taken at 5µm thickness processed in alcohol-
xylene series and was stained with haematoxylin-eosin dye. The sections were 
examined microscopically for histopathological changes19.  
Statistical analysis 
The statistical analysis was carried out using one-way analysis of variance (ANOVA) 
followed by Tukey’s post-test using Graph pad. P values <0.05 were considered as 
statistically significant condition. 
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RESULTS  
IN-SILICO DOCKING STUDIES 
Evaluation of drug likeness properties of the flavonoids  
 In silico predictions of the drug likeness properties are useful in the drug 
development process of a new chemical entity. The drug likeness property of a 
compound was evaluated based on the Lipinski’s Rule of Five. Lipinski’s Rule of five 
allows calculating the oral bioavailability parameters for the compounds used as an 
oral drug. The parameters such as molecular weight, log P, hydrogen bond donors, and 
hydrogen bond acceptors of the compound were calculated for the Lipinski’s Rule. If 
the compound shows any violation it cannot be considered for further in silico 
screening studies.   
Analysis of the receptor/ligand complex models generated after successful 
docking of the flavonoids was based on the parameters such as hydrogen bond 
interactions, п–п interactions, binding energy, RMSD of active site residues and 
orientation of the docked compound within the active site. As a general rule, in most 
of the potent anti-inflammatory compounds, both hydrogen bond and п–п hydrophobic 
interactions between the compound and the active sites of the receptor have been found 
to be responsible for mediating the biological activity. The possible structural 
fragments of the flavonoids (about 50 flavonoids) were designed with the help of 
ChemSketch and they were subjected to test their drug likeness properties with the 
help of Molinspiration server. 
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Table 5: List of flavonoids selected for docking studies 
S. 
No 
C 
code BASIC NUCLEUS 
O
O
O
R
1
R
2
R
3
R1
R2
R3  
S. 
No 
C 
code 
BASIC NUCLEUS 
O
O
O
R
1
R
2
R
3
R1
R2
R3  
 
1 F1 R1=Cl, R2=Cl, R3=H 12 F12 R1=Cl, R2=Br, R3=H 
2 F2 R1=Cl, R2=H, R3=Cl 13 F13 R1=Cl, R2=H, R3=Fl 
3 F3 R1=Cl, R2=OCH3, R3=H 14 F14 R1=Cl, R2=H, R3=NO2 
4 F4 R1=Cl, R2=Cl, R3=Cl 15 F15 R1=Cl, R2=H, R3=OCH 
5 F5 R1=Cl, R2= Cl, R3=NO2 16 F16 R1=Cl, R2=H, R3=CH3 
6 F6  R1=Cl, R2=H, R3=OH 17 F17 R1=H, R2=OH, R3=H 
7 F7 R1=Cl, R2=H, R3=NO2 18 F18  R1=Cl, R2=H, R3=H 
8 F8 R1=H, R2=H, R3=Br 19 F19 R1=Br, R2=H, R3=H 
9 F9 R1=H, R2=H, R3=CH3 NH 20 F20 R1=Cl, R2=H, R3=NH2  
10 F10 R1=Cl, R2=H, R3=Cl 21 F21 R1=OH, R2=H, R3=H 
11 F11 R1=Br, R2=H, R3=H 22 F22 R1=H, R2=H, R3=Br 
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Continued 
S. 
No 
C 
code 
BASIC NUCLEUS 
O
O
O
R
1
R
2
R
3
R1
R2
R3  
S. 
No 
C 
code 
BASIC NUCLEUS 
O
O
O
R
1
R
2
R
3
R1
R2
R3  
23 F23 R1=Cl, R2=NH2, R3=H 34 F34 R1=CH3, R2=H, R3=H 
24 F24 R1=OH, R2=H, R3=Fl 35 F35 R1=H, R2=H, R3=F 
25 F25 R1=OH, R2=H, R3=NO2 36 F36 R1=H, R2=H, R3=NO2 
26 F26 R1=Cl, R2=OCH3, R3=H 37 F37 R1=H, R2=H, R3=OCH3 
27 F27 R1=CH3, R2=H, R3=CH3 38 F38 R1=, R2=H, R3=CH3 
28 F28 R1=H, R2=H, R3=OH 39 F39 R1=H, R2=H, R3=OH 
29 F29 R1=Cl, R2=H, R3=NO2 40 F40 R1=NO2, R2=H, R3=H 
30 F30 R1=Br, R2=H, R3=Br 41 F41 R1=Cl, R2=Br, R3=H 
31 F31 R1=OH, R2=H, R3=OH 42 F42 R1=H, R2=H, R3=NH2CH3 
32 F32 R1=NO2, R2=H, R3=H 43 F43 R1=Cl, R2=H, R3=Cl 
33 F33 R1=Cl, R2=NO2, R3=H 44 F44 R1=Br, R2=H, R3=Br 
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Continued 
S. No C code 
BASIC NUCLEUS 
O
O
O
R
1
R
2
R
3
R1
R2
R3  
45 F45 R1=Cl, R2=H, R3=H 
46 F46 R1=Fl, R2=H, R3=H 
47 F47 R1=Cl, R2=H, R3=NO2 
48 F48 R1=Cl, R2=H, R3= OCH3 
49 F49 R1=Cl, R2=H, R3=CH3 
50 F50 R1=Cl, R2=H, R3=OH 
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Table 6: Drug likeness properties of the flavonoids using Molinspiration software 
Compound 
code 
 Log P Polar surface area No. of atoms 
No. of 
hydrogen 
bond 
acceptors 
No. of 
hydrogen 
bond donors 
No. of 
violations 
No. of 
rotatable 
bonds 
Enzyme 
inhibitor 
F1 0.235 47.28 29 3 0 1 1 0.13 
F2 2.615 50.13 28 3 0 0 2 0.11 
F3 3.198 73.89 23 2 0 1 1 0.23 
F4 3.411 31.23 25 2 0 1 1 0.12 
F5 2.362 76.03 221 5 0 0 2 0.16 
F6 3.709 45.23 19 3 1 0 1 0.11 
F7 2.112 30.21 19 2 0 0 1 0.21 
F8 3.307 33.45 23 3 0 0 2 0.08 
F9 2.103 30.21 70 2 0 0 1 0.21 
F10 4.563 43.21 20 3 0 0 2 0.11 
F11 5.321 30.21 45 2 0 1 1 0.44 
F12 5.180 39.45 19 2 0 1 1 0.22 
69 
 
Compound 
code 
 Log P Polar surface area No. of atoms 
No. of 
hydrogen 
bond 
acceptors 
No. of 
hydrogen 
bond donors 
No. of 
violations 
No. of 
rotatable 
bonds 
Enzyme 
inhibitor 
F13 5.044 30.21 23 2 0 1 1 0.32 
F14 4.455 75.45 22 3 0 0 2 0.14 
F15 4.334 30.21 21 5 0 0 2 0.22 
F16 5.240 30.21 19 2 0 1 1 0.13 
F17 5.017 76.03 19 2 0 1 1 0.09 
F18 4.315 45.36 18 5 0 0 2 0.16 
F19 4.515 50.44 19 2 0 0 1 0.11 
F20 2.118 33.45 19 3 1 0 1 0.36 
F21 4.491 30.21 25 3 0 0 2 0.16 
F22 4.842 39.45 19 2 0 0 1 0.42 
F23 3.187 76.03 21 5 0 0 2 0.31 
F24 4.332 76.03 21 5 0 0 2 0.63 
F25 2.158 121.86 78 3 0 0 3 0.11 
F26 4.480 76.03 21 5 0 0 3 0.24 
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Compound 
code 
 Log P Polar surface area No. of atoms 
No. of 
hydrogen 
bond 
acceptors 
No. of 
hydrogen 
bond donors 
No. of 
violations 
No. of 
rotatable 
bonds 
Enzyme 
inhibitor 
F27 4.325 76.03 21 5 0 0 2 0.32 
F28 3.623 121.86 23 8 0 0 3 0.12 
F29 3.845 76.03 23 5 0 0 2 0.06 
F30 3.197 96.26 21 6 1 0 2 0.12 
F31 3.772 79.27 23 6 0 0 3 0.13 
F32 3.738 85.27 23 6 0 0 3 0.18 
F33 4.124 76.03 21 5 0 0 2 0.15 
F34 4.95 30.21 19 2 0 0 1 0.12 
F35 4.826 30.21 19 2 0 0 1 0.43 
F36 4.102 76.03 21 5 0 0 2 0.15 
F37 5.23 30.21 19 2 0 0 1 0.25 
F38 2.255 30.21 19 2 0 0 1 0.23 
F39 4.363 30.21 31 2 0 0 1 0.65 
F40 1.684 50.41 19 3 1 0 1 0.32 
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Compound 
code 
 Log P Polar surface area No. of atoms 
No. of 
hydrogen 
bond 
acceptors 
No. of 
hydrogen 
bond donors 
No. of 
violations 
No. of 
rotatable 
bonds 
Enzyme 
inhibitor 
F41 4.142 76.03 21 5 0 0 2 0.12 
F42 4.268 33.45 21 3 0 0 2 0.21 
F43 4.611 30.21 21 2 0 0 1 0.21 
F44 4.232 39.45 20 3 0 0 2 0.56 
F45 4.042 50.44 19 3 1 0 1 0.35 
F46 4.253 50.44 45 3 1 0 1 0.38 
F47 5.120 96.26 21 6 1 0 2 0.42 
F48 4.023 50.44 19 3 1 0 1 0.13 
F49 2.156 50.44 19 3 1 0 1 0.09 
F50 4.258 96.26 58 6 1 0 4 0.18 
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Molecular docking studies 
In the present study, all the selected flavonoids showed excellent score which 
indicates that these compounds have no violations in Lipinski’s Rule of 5 (Table ). 
Based on the drug likeness score, the flavonoids were selected for the further 
prediction of in silico biological activity using AutoDock 4.2.  
 The compounds that have passed the drug likeness properties were considered 
for molecular docking studies. In silico docking study was carried out to identify the 
inhibiting potential of selected flavonoids against angiotensin converting enzyme 
(PDB ID: 1086). In this study 50 different flavonoids were selected for the in silico 
docking studies. The docking studies were performed by the use of AutoDock4.2. In 
the docking studies, if a compound shows lesser binding energy compared to the 
standard it proves that the compound has higher activity. The docking poses were 
ranked according to their docking scores and both the ranked list of docked ligands 
and their corresponding binding poses. Binding energy of the individual compounds 
were calculated using the following formula, 
Binding energy = A+B+C-D 
Where, A denotes the final intermolecular energy + vander Waals energy (vdW) + 
hydrogen bonds + desolvation energy + electrostatic energy (kcal/mol). B denotes the 
final total internal energy (kcal/mol). C denotes the torsional free energy (kcal/mol) 
and D denotes the unbound system energy (kcal/mol). 
All the 50 flavonoids showed binding energy ranging between -10.44 kcal/mol 
to -6.59 kcal/mol. F1 flavonoid showed excellent binding energy -9.50 kcal/mol and 
standard enalapril -6.59 kcal/mol. F1 flavonoid showed higher binding energy when 
compared to other synthetic flavonoids. F1-F5 compounds showed excellent binding 
energy when compared to rest of the selected compounds and the standard. These 
results suggested that the F1 to F5 compounds possess the potential angiotensin 
converting enzyme inhibitory activity than the other selected flavonoids and the order 
of potency is found to be F1>F2>F3>F4>F5. 
The other two parameters like inhibition constant (Ki) and intermolecular 
energy were also determined. Inhibition constant is directly proportional to binding 
73 
 
energy. The selected flavonoids showed inhibition constant ranging between-8.36 to -
8.12 Nm. F1and F2 flavonoids showed excellent inhibition constant -8.36 and -8.15, 
standard enalapril 6.13 nM. F1 flavonoid showed higher inhibition constant when 
compared to other selected flavonoids. Intermolecular energy is also directly 
proportional to binding energy. Flavonoids showed intermolecular energy ranging 
between -6.23 to -7.13 kcal/ mol. F1and F2 flavonoid showed excellent intermolecular 
energy -6.23 and -7.13 standard enalapril -7.58 kcal/ mol.  
 
Table7: In silico docking results of ACE [PDB ID:1086] inhibition by selected 
compounds 
SL.NO FLAVONOIDS 
BINDING 
ENERGY 
INHIBITION 
CONSTANT 
(nM) 
INTERMOLECULAR 
ENERGY 
1 F1 -8.36 255.13 -6.23 
2 F2 -8.15 151.23 -7.13 
3 F3 -6.09 259.3 -7.26 
4 F4 -7.32 158.25 -7.23 
5 F5 -8.12 360.28 -8.9 
6 F6 -7.36 256.42 -7.26 
7 F7 -6.90 465.23 -10.62 
8 F8 -8.51 580.05 -11.19 
9 F9 -7.68 2.35 -9.17 
10 F10 -8.56 534.69 -9.45 
11 F11 -9.4 128.03 -10.3 
12 F12 -7.33 4.25 -8.22 
13 F13 -7.49 198.05 -8.15 
14 F14 -8.73 397.03 -10.22 
15 F15 -8.92 288.21 -11.61 
16 F16 -7.8 1.92 -9.29 
17 F17 -8.48 604.32 -9.98 
18 F18 -10.34 26.42 -12.13 
19 F19 -8.12 1.12 -9.91 
20 F20 -8.1 1.15 -9.89 
21 F21 -7.69 2.31 -9.48 
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22 F22 -9.12 207.28 -10.91 
23 F23 -9.29 153.75 -11.08 
24 F24 -9.56 99.06 -11.94 
25 F25 -10.05 42.66 -12.44 
26 F26 -9.36 138.22 -10.55 
27 F27 -9.07 224.37 -10.26 
28 F28 -8.42 670.04 -10.21 
29 F29 -8.47 616.62 -9.96 
30 F30 -8.56 533.89 -10.05 
31 F31 -8.16 1.04 -9.66 
32 F32 -9.12 207.94 -10.91 
33 F33 -8.6 498.09 -9.79 
34 F34 -8.69 425.16 -11.08 
35 F35 -8.85 328.39 -9.74 
36 F36 -9.5 108.57 -10.4 
37 F37 -7.45 3.46 -8.35 
38 F38 -8.17 1.02 -10.56 
39 F39 -7.49 3.24 -10.17 
40 F40 -9.44 119.88 -10.64 
41 F41 -10.44 22.07 -11.64 
42 F42 -9.05 233.23 -10.24 
43 F43 -10.15 36.48 -11.34 
44 F44 -7.63 2.57 -10.01 
45 F45 -8.24 917.79 -10.62 
46 F46 -10.0 46.38 -11.5 
47 F47 -7.9 1.61 -8.5 
48 F48 -8.1 1.15 -8.7 
49 F49 -7.04 6.93 -7.64 
50 F50 -7.94 1.51 -8.84 
 
F1-F5 compounds showed excellent inhibition constant and intermolecular 
energy when compared to rest of the selected compounds and the standard. These 
results suggested that the F1 to F5 compounds possess the potential angiotensin 
converting enzyme inhibitory activity than the other selected flavonoids and the order 
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of potency is found to be F1>F2>F3>F4>F5. These results further proved that the F1 
to F5 compounds possess the better angiotensin converting enzyme inhibitory activity 
than the other selected flavonoids.  
 
DOCKING ORIENTATIONS 
Binding of selected flavonoids with ACE [1086] 
 The potential binding sites of the F1 was found that TYR334, PHE330, 
PHE331, PHE288,TRP279, SER288, LE287 and the binding sites of the F2 was found 
to be ASP72, TYR121, PHE288, ARG289, PHE330, PHE331 
 
 
Figure 7: F1 – 2 Chloro & F2 – 4 Chloro                
 
 
 
 
 
 
Figure 8: F3 – 2 ethoxy & F4 – 2,4 Dichloro 
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 Figure 9: F5 – 2 Chloro, 5 Nitro & Enalapril                         
               
           
 
 
 
 
 
This proves that the effective binding sites were present in the selected 
flavonoids such as F1(2-ethoxy), F2 (2,4-dichloro), F3 (2-chloro), F4 (4-chloro), F5 
(2-chloro, 5-nitro) when compared with the standard and also it shows the inhibitory 
potential of the angiotensin converting enzyme. 
 
Table8: Docking orientations of the selected flavonoids and enalapril 
 
C. code Binding interaction with amino acid residue 
F1 
ZN707, HIS353, TYR520, TYR523, VAL360, VAL379, 
PHE527, GLN281 
F2 
ALA301, HIS353, HIS383, HIS513, ZN701, TYR523, 
TRP270, ASP423, GAN 281 
F3 
GLU384, HIS333, HIS387, HIS353, SER528, ZN701, 
TYR523, HIS513, LYS511, TRP279, GLN281 
F4 
SER385, HIS387, GLU224, HIS513, HIS353, PHE451, 
GLN281, PHE527, VAL260, ZN201 
F5 
VAL370, VAL330, TYR123, TYR520, GLN280, 
GLU384, ALA354 
Enalapril 
HIS383, HIS353, LYS511, TYR520, GLN281, TYR623, 
LYS450 
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The standard enalapril and selected flavonoids possess binding similarity of the 
aminoacids with the target. Due to this binding site simiarity, these flavonoids possess 
inhibitory activity towards angiotensin converting enzyme similar to that of standard. 
Since, the potential binding parameters were identified in the selected flavonoids in 
the in silico studies. So, the flavonoids has the chance to bind the amino acid residues 
in the target so effectively than the standard. This result further strenghthen the 
inhibitory potential of flavonoids than that of the standard. On the basis of the above 
study, all the selected flavonoids showed better angiotensin converting inhibitory 
activity. Among the selected flavonoids F1, F2, F3, F4 and F5 showed excellent 
binding interactions and orientations towards the target enzyme. This may be attributed 
due to the differences in the functional groups in these compounds.Thus, these 
compounds further selected for synthesis, in vitro and in vivo angiotensin converting 
enzyme inhibitory activity. 
ADMET studies: 
 ADMET studies were carried out using MedChem Designer software for the 
compounds selected for synthesis and the results are tabulated in Table 9.  
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Table 9: ADMET properties of the synthesized compounds 
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F1 45.3694 -0.235 2 0.30069 1.958 5 1 0.6823 2.056 1 0.94702 0 0.30816 2 0 
F2 49.3657 2.615 3 0.19841 3.502 1 1 0.2586 2.581 1 0.953642 0 0.15842 2 0 
F3 53.1285 3.198 3 6.12380 3.976 4 1 0.8535 4.430 1 0.980132 0 0.20103 2 0 
F4 62.1895 3.411 2 0.22534 4.728 4 1 0.71287 2.985 1 0.953642 0 0.22181 2 0 
F5 61.701 2.362 4 0.690774 3.425 3 1 0.5861 3.425 1 0.96026 0 0.00326 2 0 
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SYNTHESIS OF FLAVONOIDS 
 The percentage yield of all the synthesized compounds ranged from 75 to 86%. 
The melting point was determined by using MR-VIS visual melting range apparatus 
and the melting point ranged from 113.5°C to 235.5°C. The percentage yield, melting 
point of the synthesized flavonoids were provided. 
Table10: Percentage yield and melting point and of synthesized flavonoids 
 
 
 
 
 
 
Compound code 
Percentage 
yield 
Melting point 
F1 75% 113.5°C 
F2 76% 235.5°C 
F3 87% 168.4°C 
F4 75% 183.2°C 
F5 86% 197.3°C 
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IN VITRO ACETYLCHOLINESTERASE INHIBITORY ASSAY 
A total of 50 compounds were used for docking studies and based on the results 
of binding energies, inhibition constant and intermolecular energies, 5 compounds 
were selected and synthesized. The 5 synthesized flavonoids were tested for inhibition 
of angiotensin converting enzyme. The synthesized flavonoids were dissolved in water 
and suitable concentration (0.2 - 3.2µg/ml) was prepared based on the pilot study. 
Enalapril was used as reference standard for comparison of results of the test 
compounds. The absorbance of all the synthesized flavonoids (F1 to F5 and enalapril) 
decreased upon increasing the concentrations in a dose dependent manner. The 
percentage inhibition was calculated for all the synthesized flavonoids (F1 to F5) and 
for enalapril. A dose dependent increase in percentage of inhibition was observed for 
standard and synthetic flavonoids. The percentage inhibition of enalapril ranged 
between 25.62 to 100.13% and the IC50 was found to be 19.85 ± 25µg/ml. The 
percentage of inhibition for compound F1 (2-chloro) ranged from 49.55 to 101.08% 
and its IC50was found to be 0.287 ± 0.13 µg/ml. For compound F2 (4-chloro) the 
percentage inhibition ranged from 32.27to 63.54% and the IC50 value was found to be 
1.464 ± 0.23 µg/ml. The percentage inhibition of acetylcholinesterase enzyme with F3 
(2-ethoxy) compound was found to be from 42.41 to 60.54 % and the IC50 was 0.803 
± 0.03 µg/ml. The F4 (2,4-dichloro) compound had IC50 value of 1.500 ± 0.16 µg/ml 
and its percentage inhibition ranged from 31.06 to 62.71. The percentage inhibition for 
F5 (2-chloro,5-nitro) ranged between 32.46 to 92.26% respectively and IC50 was found 
to be 0.618 ± 0.41µg/ml. Among the 5 synthetic compounds, F1 and F2 had greater 
percentage of inhibition at 3.2 µg/ml concentration with 101.08% activity. Excellent 
inhibitory activity was possessed by since for this compound the IC50 was 0.287 ± 0.13. 
The order of potency based on IC50 for synthesized flavonoids to angiotensin 
converting enzyme inhibitory activity was found to be F1>F2>F3>>F4>F5 
respectively.  
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Table 11: Percentage inhibition of synthesized flavonoids to angiotensin converting enzyme 
Concentration 
(µg/ml) 
Percentage inhibition (%) of ACE 
IC50value 
F1 F2 F3 F4 F5 
50 27.94 ± 19 27.19 ± 23 56.58 ± 35 22.38 ± 22 56.52 ± 37 259.65 ± 16 
100 40.07 ± 31 35.16 ± 37 57.41 ± 47 29.38 ± 37 59.34 ± 37 325.36 ± 17 
200 48.15 ± 65 43.13 ± 35 76.03 ± 09 57.13 ± 36 73.61 ± 29 70.21 ± 35 
400 52.59 ± 52 54.76 ± 09 80.60 ± 57 60.49 ± 21 80.08 ± 36 165.52 ± 22 
800 73.89 ± 24 75.99 ± 57 88.05 ± 05 78.85 ± 18 90.58 ± 28 73.89 ± 24 
 
All the determinations were carried out in triplicate and the values are expressed as the Mean ± SEM. F1, F2, F3, F4, F5 are different 
flavonoids. The standard drug enalapril. 
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SPECTRAL MEASUREMENTS OF SYNTHESIZED FLAVONOIDS 
Compound code: F3 
IUPAC NAME 3-(2-chloro benzoyl)-2-(2-chloro phenyl)-4H-chromen-4-one 
UV- SPECTRUM Ȝmax – 375nm (solvent – dimethyl sulphoxide) 
IR SPECTRUM 
(KBr Cm-1) 
3447.13(Ar C-H), 1675.84(C=O), 
1474.31(Ar C=C),921.80 (C-O), 772.35(C-Cl) 
MASS 
SPECTRUM 
395.21 M+ ion peak 
 
Compound code: F4 
IUPAC NAME 3-(4-chloro benzoyl)-2-(4-chloro phenyl)-4H-chromen-4-one 
UV- SPECTRUM Ȝmax –360   nm (solvent – dimethyl sulphoxide) 
IR SPECTRUM 
(KBr Cm-1) 
3393.13(Ar C-H), 1630.23(C=O),1424.02(Ar C=C),  
943.60  (C-O), 738.53 (C-Cl) 
MASS 
SPECTRUM 
395.37, M+ ion peak 
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IN VIVO STUDIES 
Acute toxicity studies and selection of dose for in vivo studies  
Among the 5 compounds selected for in vitro angiotensin converting enzyme 
inhibitory assay F3 and F4 flavonoids were found to possess good activity in inhibiting 
the enzyme and these compounds were selected and used for further in vivo assays. 
Acute toxicity was determined as per OECD guidelines (420) employing fixed dose 
procedure for selecting the dose for biological activity. For acute toxicity studies 
female Wistar rats weighing 180-200g were taken and they were fasted overnight 
before the experimental day. Overnight fasted rats were weighed and body weight 
determined for dose calculation and the test flavonoids (F3-2-chloro and F4-4-chloro) 
were administered orally. Sighting study was conducted with a lower dose of 5 mg/kg 
using 0.5% CMC. After administration, the animals were observed for occurrence of 
toxic effects. No toxic effect were observed and after sufficient interval of time (2-3 
days) the second animals were administered with 50 mg/kg dose of test flavonoids. 
Similar observations were made as before and since the doses was non-toxic the third 
animal was administered with 300 mg/kg. This dose also did not exhibit any toxicity 
or morbidity and therefore the last and highest dose in fixed dose procedure of 2000 
mg/kg were administered to fourth animal. No toxicity was noticed for highest doses. 
Signs and symptoms of toxicity and death if any were observed individually for each 
rat at 0, 0.5, 1, 2, 3 and 4 h for first 24 h and thereafter daily for 14 days. Diet was 
given to the animals after the 4th hours of dosing. The animals were observed twice 
daily for 14 days and body weight changes, food and water consumption etc., were 
noted. In acute toxicity studies, it was found that the animals were safe up to a 
maximum dose of 2000 mg/kg of body weight. There were no changes in normal 
behavioural pattern and no signs and symptoms of toxicity and mortality were 
observed. As per the OECD 420 guidelines F3-2-chloro flavonoid and F4-4-chloro can 
be included in the category 5 or unclassified category of globally harmonized 
classification system (GHS). Hence, based on these results the F3 (2-chloro) and F4(4-
chloro) flavonoids were considered non-toxic and 1/10th and 1/20th dose were used for 
the biological evaluation (cardioprotective activity) and the studies were conducted at 
dose levels of 100 and 200 mg/kg body weight. 
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Table 12: OBSERVATIONS DONE FOR THE ACUTE ORALTOXICITY STUDY- F3 (2-CHLORO) & F4 (4-CHLORO) 
COMPOUNDS 
Observation  Score for 
Normal 
animal 
Half 
an 
hour 
Four 
hours 
24 
Hours 
Day 
2 
Day 
4 
Day 
6 
Day 
8 
Day 
10 
Day 
12 
Day 
14 
Lethality  Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Group Dispersion 0 0 0 0 0 0 0 0 0 0 0 
Locomotor Activity 4 4 4 4 4 4 4 4 4 4 4 
Restlessness 0 0 0 0 0 0 0 0 0 0 0 
Lethargy 0 0 0 0 0 0 0 0 0 0 0 
Writhing 0 0 0 0 0 0 0 0 0 0 0 
Stereotyped behavior 0 0 0 0 0 0 0 0 0 0 0 
Tremors 0 0 0 0 0 0 0 0 0 0 0 
Twitches 0 0 0 0 0 0 0 0 0 0 0 
Convulsions 0 0 0 0 0 0 0 0 0 0 0 
Exophthalmos 0 0 0 0 0 0 0 0 0 0 0 
Respiration 0 0 0 0 0 0 0 0 0 0 0 
Alertness 4 4 4 4 4 4 4 4 4 4 4 
Group startle response 4 4 4 4 4 4 4 4 4 4 4 
NAD  Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
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Observation 
Score for 
normal 
animal 
Time of individual observations 
Half 
an 
hour 
Four 
hours 
24 
Hours 
Day 2 Day 4 Day 6 Day 8 Day 10 Day 12 Day 14 
Loss if Righting reflex 0 0 0 0 0 0 0 0 0 0 0 
Abnormal body carriage 0 0 0 0 0 0 0 0 0 0 0 
Abnormal gait 0 0 0 0 0 0 0 0 0 0 0 
Straub tail 0 0 0 0 0 0 0 0 0 0 0 
Piloerection 0 0 0 0 0 0 0 0 0 0 0 
Touch response 4 4 4 4 4 4 4 4 4 4 4 
Fearfulness 4 4 4 4 4 4 4 4 4 4 4 
Pinna reflex 4 4 4 4 4 4 4 4 4 4 4 
Corneal reflex 4 4 4 4 4 4 4 4 4 4 4 
Catalepsy 0 0 0 0 0 0 0 0 0 0 0 
Passivity 0 0 0 0 0 0 0 0 0 0 0 
Aggressiveness 0 0 0 0 0 0 0 0 0 0 0 
Body tone 4 4 4 4 4 4 4 4 4 4 4 
Grip strength 4 4 4 4 4 4 4 4 4 4 4 
Paralysis 0 0 0 0 0 0 0 0 0 0 0 
Cutaneous blood flow 4 4 4 4 4 4 4 4 4 4 4 
Cyanosis 0 0 0 0 0 0 0 0 0 0 0 
Salivation 0 0 0 0 0 0 0 0 0 0 0 
Lacrimation 0 0 0 0 0 0 0 0 0 0 0 
Ptosis 0 0 0 0 0 0 0 0 0 0 0 
Pupil diameter 4 4 4 4 4 4 4 4 4 4 4 
Pain response 4 4 4 4 4 4 4 4 4 4 4 
Diarrhea 0 0 0 0 0 0 0 0 0 0 0 
Vocalization 0 0 0 0 0 0 0 0 0 0 0 
Increased urination 0 0 0 0 0 0 0 0 0 0 0 
Grooming 4 4 4 4 4 4 4 4 4 4 4 
NAD  Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
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Table13: MORTALITY RECORD FOR F3(2-CHLORO) COMPOUND IN ACUTE ORAL TOXICITY STUDY 
 
Dose 
Sighting study Main study 
5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 
No. of 
animals 
1 2 3 4 5 6 7 8 9 
Body weight 
(g) 
188 
 
188 
 
184 
 
 
196 
 
189 
 
190 
 
193 
 
192 
 
 
188 
 
Sex Female Female Female Female Female Female Female Female Female 
30 min Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
1 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
2 h Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
3 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
4 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 1 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 2 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 3 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 4 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 5 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 6 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 7 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 8 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 9 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
continued 
87 
 
 
Dose 
Sighting study Main study 
5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 
No. of 
animals 
 
1 
 
 
2 
 
3 4 5 6 7 8 9 
Body 
weight (g) 189 188 187 190 195 
 
190 
 
193 
 
192 
 
 
190 
 
Sex Female Female Female Female Female Female Female Female Female 
Day 10 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 11 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 12 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 13 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Mortality 0/0 0/0 0/0 0/0 0/0 
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Table14: MORTALITY RECORD FOR F4 (4-CHLORO) COMPOUND IN ACUTE ORAL TOXICITY STUDY 
 
Dose 
Sighting study Main study 
5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 
No. of 
animals 
 
1 
 
2 3 4 5 6 7 8 9 
Body weight 
(g) 
 
188 
 
 
179 
 
188 
 
196 
 
199 
 
190 
 
 
189 
 
189 
 
188 
 
Sex Female Female Female Female Female Female Female Female Female 
30 min Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
1 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
2 h Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
3 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
4 h Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 1 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 2 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 3 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 4 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 5 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 6 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 7 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 8 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 9 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
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Dose 
Sighting study Main study 
5 mg/kg 50 mg/kg 300 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 2000 mg/kg 
No. of animals 1 2 3 4 5 6 7 8 9 
Body weight 
(g) 
193 
176 
178 
176 
186 
187 
192 
195 
200 
198 
190 
187 
190 
193 
192 
194 
190 
191 
Sex Female Female Female Female Female Female Female Female Female 
Day 10 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 11 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 12 Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  
Day 13 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Day 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Mortality 0/0 0/0 0/0 0/0 0/0 
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Table 15: Effect of F3 (2-chloro) and F4 (4-chloro) flavonoids on body weight in 
doxorubicin-induced myocardial infarction in rats 
 
 
Values are expressed as mean ± SEM (n=6).  
Values in parentheses are the percent increase or decrease from their corresponding 
initial readings.  
* denotes p < 0.05; ns denotes p > 0.05 when compared to initial readings; when 
compared to the initial readings (Student’s Paired‘t’-test);  
 
 
 
 
 
 
 
 
 
Dose  
Body weight (g) 
Initial Final  
0.5%w/v of CMC 147.83±5.16 167.16±5.55ns 
Doxorubicin 
(10mg/g) 
187.66±9.26 197.66±5.17* 
F3-2-chloro (100mg/k) 178.16±4.91 184.10±5.17ns 
F3-2-chloro (200mg/kg 186.10±5.22 195.33±3.13ns 
F4-4-chloro (100mg/kg 174.16±3.92 189.16±6.50ns 
F4-4-chloro (200mg/kg) 174.33±4.44 195.10±6.69ns 
Enalapril (10mg/kg) 176.33±3.82 198.16±4.10ns 
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Table 16: EFFECT OF 2-CHLORO AND 4-CHLORO FLAVONOIDS ON 
SERUM MARKERS IN DOXORUBICIN-INDUCED MYOCARDIAL 
INFARCTION IN RATS 
 
Values are expressed in mean ± SEM (n=6) 
# denotes p < 0.05, ## denotes p < 0.01 and ### denotes p < 0.001 when compared to 
vehicle control; 
*denotes p < 0.05, ** denotes p < 0.01 and *** denotes p <0.001 when compared to 
negative control (one way ANOVA followed by Tukey’s test0) 
 
 
 
DOSE 
MARKERS OF MI LIVER FUNCTION TESTS 
CK-MB 
(IU/L) 
LDH 
(IU/L) 
TROPO
NIN- I 
ALT 
(IU/L) 
AST 
(IU/L) 
ALP 
(IU/L) 
0.5%w/v of 
CMC 
1786.25 ± 
232.54 
 
55.85 ± 
9.013 
- 
7.50 ±  
6.51 
35.29 ± 
32.67 
595.38 ±  
110.81 
Doxorubicin 
(10mg/g) 
3259.30 ± 
412.62# 
71.39 ± 
4.907# 
+ 
249.66 ±  
4.30** 
505.05 ±  
0.92### 
1720.41 ±  
119.25## 
F3-2-chloro 
(100mg/k) 
1918.17 ± 
372.46* 
37.37 ± 
2.053* 
- 
41.19 ±  
3.80*** 
4.38 ±  
1.08*** 
990.40 ±  
126.57* 
F3-2-chloro 
(200mg/kg 
1748.16 ± 
215.24* 
28.37 ± 
1.747** 
- 
32.92 ±  
6.04*** 
6.94 ±  
2.79*** 
385.06 ±  
95.98*** 
F4-4-chloro 
(100mg/kg 
 
2875.13 ± 
461.90* 
 
33.65 ± 
0.919* 
 
- 
49.41 ±  
4.24*** 
8.28 ±  
1.34*** 
610.48 ±  
81.16** 
F4-4-chloro 
(200mg/kg) 
 
2576.26 ± 
371.45* 
26.33 ± 
3.088** 
- 
2.20 ±  
4.24*** 
37.39 ±  
31.97*** 
787.71 ±  
41.02** 
Enalapril 
(10mg/kg) 
 
2907.60 ± 
334.29** 
 
47.51 ± 
3.71** 
- 
2.78 ±  
0.26** 
17.3 ±  
4.61** 
587.23 ±  
17.87** 
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Table 17: EFFECT OF 2-CHLORO AND 4-CHLORO FLAVONOIDS ON 
LIPID PROFILE IN DOXORUBICIN-INDUCED MYOCARDIAL 
INFARCTION IN RATS 
 
 
Values are expressed in mean ± SEM (n=6) 
# denotes p < 0.05 and ## denotes p < 0.01 when compared to vehicle control; 
*denotes p < 0.05, ** denotes p < 0.01 and *** denotes p <0.001 when compared to 
negative control (One way ANOVA followed by Tukey’s test)
DOSE 
(mg/kg) 
 
TRIGLYCERIDES HDL LDL VLDL 
0.5%w/v of 
CMC 
 
193.29 ± 17.11 22.33 ± 0.52 68.2 ± 0.46 38.65 ± 3.42 
Doxorubicin 
10mg/kg 
973.68 ± 17.39## 6.12 ± 1.17## 98.60 10.62## 174.73 ± 3.47# 
F3-2-chloro 
(100mg/kg) 
153.40 ± 11.28** 50.07 ± 2.48*** 61.31 9.11** 30.68 ± 2.25*** 
F3-2-chloro 
(200mg/kg 
152.35 ± 18.35** 
17.27 ± 
1.813*** 
69.23 ± 6.11** 30.46 ± 3.67*** 
F4-4-chloro 
(100mg/kg 
184.24 ± 17.45* 21.68 ± 0.94*** 51.33 ± 5.20** 36.84 ± 3.49*** 
F4-4-chloro 
(200mg/kg 
147.53 ± 18.93** 35.30 ± 1.55** 60.25 ± 20** 29.50 ± 3.78*** 
Enalapril 
(10mg/kg) 
212.99 ± 12.98** 14.81 ± 2.89** 71.53 3.20** 42.59 ± 2.59** 
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Table 18: EFFECT OF F1 (2-CHLORO) AND F4 (4-CHLORO) 
FLAVONOIDS ON TOTAL PROTEIN & MDA IN HEART TISSUE OF  
DOXORUBICIN-INDUCED MYOCARDIAL INFARCTION IN RATS 
DOSE  
TOTAL PROTEN 
 
(mmoles/min/mg) 
MDA 
(µmoles/min/mg) 
0.5%w/v of  
CMC 
2.20 ± 0.10 17.46 ± 0.60 
Doxorubicin 
10mg/kg 
0.85 ± 0.11# 48.17 ± 0.74## 
2-chloro 
(100mg/kg) 
1.30 ± 0.10* 15.25 ± 0.52** 
2-chloro 
(200mg/kg 
1.50 ± 0.12* 14.36 ± 0.62** 
4-chloro 
(100mg/kg 
1.08 ± 0.12* 11.52 ± 0.53** 
4-chloro 
(100mg/kg 
1.80 ± 0.18* 12.367 ± 0.62** 
Enalapril 
(10mg/kg) 
2.03 ± 0.15* 15.25 ± 0.25** 
 
Values are expressed in mean ± SEM (n=6). 
# denotes p < 0.05 and ## denotes p < 0.01 when compared to vehicle control; * 
denotes p < 0.05 and ** denotes p < 0.05 when compared to negative control.  
(One way ANOVA followed by Tukey’s test).  
 
  
 94 
 
Table 19: EFFECT OF 2-CHLORO AND 4-CHLORO FLAVONOIDS ON 
ENZYMATIC AND NON-ENZYMATIC ANTIOXIDANTS IN THE HEART 
TISSUE OF DOXORUBICIN-INDUCED MYOCARDIAL INFARCTION IN 
RATS 
 
 Values are expressed in mean ± SEM (n=6) 
# denotes p < 0.05 and ## denotes p < 0.01 when compared to vehicle 
control;*denotes p < 0.05, ** denotes p < 0.01 and *** denotes p <0.001 when 
compared to negative control (One way ANOVA followed by Tukey’s test). 
 
DOSE (mg/kg) 
ENZYMATIC ANTIOXIDANTS 
NON-ENZYMATIC 
ANTIOXIDANT 
SOD 
(µmoles/mi
n/mg 
protein) 
CAT 
(mmoles
/min/mg 
protein) 
GPX 
(µmole
s/min/
mg 
protein) 
GSSH 
(µmoles/
min/mg 
protein) 
GSH 
(µmoles/min/mg 
protein) 
0.5%w/v of   
CMC 
36.71 ± 
0.807 
60.568 ± 
2.12 
14.365 
± 0.44 
15.89 ± 
0.44 
14.54 ± 0.25 
Doxorubicin 
10mg/kg 
2.390 ± 
1.31## 
4.064 ± 
2.02## 
1.83 ± 
0.13## 
1.40 ± 
0.0036## 
1.52 ± 0.08## 
F3-2-chloro 
(100mg/kg) 
25.060 ± 
0.10* 
55.358 ± 
0.17** 
13.120 
± 0.12** 
11.78 ±  
0.39*** 
13.550 ± 0.14** 
F3-2-chloro 
(200mg/kg 
44.957 ± 
0.09** 
56.808 ± 
0.27** 
13.768 
± 0.22** 
11.84 ± 
0.33*** 
14.680 ± 0.19** 
F4-4-chloro 
(100mg/kg 
36.030 ± 
0.20* 
59.96 ± 
0.13** 
15.123 
± 0.21** 
8.268 ± 
0.12** 
14.251 ± 0.023** 
 
F4-4-chloro 
(200mg/kg 
55.065 ± 
0.05*** 
61.89 ± 
0.23*** 
15.656 
± 0.32** 
11.177 ± 
0.05*** 
15.142 ± 0.025** 
Enalapril 
(10mg/kg) 
57.135 ± 
0.11*** 
63.905 ± 
0.24*** 
13.505 
± 0.28** 
10.864 ± 
1.35*** 
14.673 ± 0.16** 
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Effect of synthesized flavonoids on cardiac markers and liver function tests  
CK-MB, LDH and troponin-I levels were measured in all treatment groups. In 
DOX alone (negative control) treated rats a significant elevation (3259.30 ± 412.62) 
of markers were observed confirming the occurrence of MI on comparison to control 
group. Treatment with F3-2-chloro-100 and F3-2-chloro-200 mg/kg doses resulted in 
reduction of cardiac markers. The level of CK-MB in F3-2-chloro and F4-4-chloro 
was found to be 1918.17 ± 372.46 and 1748.16 ± 215.24 at 100 and 200 mg/kg dose. 
Similarly, with F4 (100 mg/kg), the level of CK-MB at 100 mg/kg dose was found to 
be 2875.13 ± 461.90 and at 200 mg/kg dose (F4) it decreased to 2576.26 ± 371.45. 
The level of CK-MB for standard drug (enalapril) treatment was found to be 2907.60 
± 334.29. LDH levels were also decreased in F3 (100 mg/kg) to 37.37 ± 2.05 and in 
F3 (200 mg/kg) it further reduced to 28.37 ± 1.74 and this shows higher concentration 
a better effect. Likewise, in F4 (100 mg/kg) and F4 (200 mg/kg) treated group a 
significant reduction of LDH was noticed with values of 33.65 ± 0.919 and 26.33 ± 
3.08 respectively. The compounds F4 (100 mg/kg) and F4 (200 mg/kg) reduced LDH 
levels effectively compared to F3 (100 mg/kg) and F3 (200 mg/kg). The troponin-I 
levels were decreased in all treatment groups when compared to negative control group 
showing the occurrence of MI. The level of ALT, AST and ALP is increased during 
MI and these levels were effectively reduced on treatment with synthesized 
compounds F3 (100 mg/kg), F3 (200 mg/kg), F4 (100 mg/kg) and F4 (200 mg/kg).  
Estimation of serum lipid profile in rats treated with flavonoids  
  MI infarction induction with DOX resulted in elevation of triglycerides, total 
cholesterol, LDL and VLDL and reduction of HDL levels. Triglycerides level in 
negative control group was found to be 193.29mg/dl when compared to control 173.68 
mg/dl. Treatment with F3 at both doses reduced the triglyceride values significantly to 
153.40 and 152.35 ± 06 mg/dl. The results obtained with F4 (100 mg/kg) and F4 (200 
mg/kg) was found to be 184.24 and 147.53 mg/dl and it can be confirmed that F4 at 
200 mg/kg dose level effectively reduced the triglyceride level. The level of bad 
cholesterol (LDL) was found to be higher for negative control group 98.60 mg/dl and 
treatment with F4 (100 mg/kg) and F4 (200 mg/kg) markedly lowered the levels 
compared to negative control group with values of 51.33 and 60. 25 mg/dl when 
compared to F3 (100 mg/kg) and F3 (200 mg/kg) with 61.31 and 69.23 respectively. 
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Better control was noticed for F4 (100 mg/kg) and F4 (200 mg/kg). The level of HDL 
was reduced in negative control group and treatment with synthesized flavonoids 
elevated the levels. Elevation of HDL was noticed in F4 (200 mg/kg)  group to 21.68 
and 17.27 in F4 (100 mg/kg) and group and effective increase in the levels were 
noticed compared to negative control treated rats.  
Estimation of MDA levels in heart tissue homogenate 
The end product of lipid peroxidation, MDA was elevated in negative control 
group to 48.173 and treatment with F3 (100 mg/kg) the MDA level reduced to 15.25 
and with F3 (200 mg/kg) it was found to be 14.36. Reduction in MDA level was 
observed for F4 (100 mg/kg) and F4 (200 mg/kg) and the values were found to be 
12.36 and 11.52. Treatment with synthesized flavonoids for 28 days effectively 
reduced the MDA level and this marks that the test compounds has the potential to 
control lipid peroxidation during occurrence of MI with DOX. 
Antioxidant status of synthesized flavonoids 
The enzymatic antioxidants SOD, CAT, GPX and GSSH levels were reduced 
in negative control group. This denotes that MI occurrence after DOX administration. 
Treatment with synthesized flavonoids markedly elevated the levels of enzymatic 
antioxidants such as SOD, CAT, GPX and GSSH levels and occurrence of MI is 
markedly reduced in treatment groups and this is noticed by an increase in levels of all 
enzymatic antioxidants in heart tissue homogenates. The non-enzymatic antioxidant 
such as GSH was found to be reduced in negative control group when compared to 
normal control. Treatment with F3 (100 mg/kg), F3 (200 mg/kg), F4 (100 mg/kg) and 
F4 (200 mg/kg) significantly restored the elevated level of GSH. The treatment groups 
were compared with standard drug enalapril and a similar increase in levels of 
antioxidant levels were noticed. 
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Figure 10: Histopathology of heart tissue  
Group I (control) rats -normal myocardium with normal myocytes and no evidence of 
architectural destruction/ oedema/ inflammatory infiltrates/ necrosis.  
Group II (Negative control) severe architectural destruction, edematous stroma, 
scattered infiltration of lymphocytes and extravasated RBC and areas of haemorrhage 
with congested blood vessels.  
Group III – F3 (100 mg/kg) myocardium shows mild loss of striation and stroma with 
pigmented laden macrophages, lymphocytic infiltration and haemorrhage with 
congested blood vessels.  
Group IV – F3 (200 mg/kg) shows normal architecture of myocardium with infiltration 
of stroma.  
Group V- F4 (100 mg/kg) exhibits normal architecture of myocardium with scattered 
lymphocytic infiltrations and the mild congestion of blood vessels. 
Group VI- F4 (200 mg/kg) showed heart with normal regular architecture and normal 
myocytes. There was no evidence of architectural destruction/ necrosis. 
Group VII – standard drug- normal myocardium architecture with normal myocyte and 
no evidence of architectural destruction/ oedema/ inflammatory infiltrates/ necrosis. 
  
I II 
III IV 
V VI 
VII 
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Group I (control) rats has shown heart with normal myocardium with normal 
myocytes. The blood vessels showed mild congestion and there was no evidence of 
architectural destruction/ oedema/ inflammatory infiltrates/ necrosis.  
Group II (Negative control) has shown myocardium with severe architectural 
destruction. Stroma was edematous with scattered infiltration of lymphocytes and 
extravasated RBC. The blood vessels showed significant pathology.  
The heart sections of Group III - FI (100 mg/kg) showed myocardium with mild loss 
of striation and stroma showed pigmented laden macrophages, lymphocytic infiltration 
and areas of hemorrhage with congested blood vessels.  
Group IV - FI (200 mg/kg) treated rats has shown myocardium with normal 
architecture and infiltration of stroma was noticed and the blood vessels exhibited no 
significant pathology. 
Group V- F2 (100 mg/kg) heart exhibited myocardium with normal architecture. 
Stroma was scattered with lymphocytic infiltrations and the blood vessels showed mild 
congestion. 
Group VI- F2 (200 mg/kg) the sections showed heart with normal myocardium with 
normal regular architecture and normal myocytes. The blood vessels showed no 
congestion. There was no evidence of architectural destruction/ necrosis. 
Group VII – standard drug treated rats shows heart with normal myocardium with 
normal regular architecture with normal myocyte. The blood vessels were normal and 
there was no evidence of architectural destruction/ edema/ inflammatory infiltrates/ 
necrosis. 
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DISCUSSION 
BIOCHEMICAL ESTIMATION OF SERUM PARAMETERS 
MARKERS FOR MYOCARDIAL INFARCTION 
The present study revealed doxorubicin treated rats showed significant increase 
in the levels of diagnostic marker enzymes like CK-MB, LDH and troponin I in the 
serum and this may be due to the leakage of enzymes from the heart as a result of 
necrosis induced by doxorubicin77. The elevated levels of these enzymes are an 
indicator of the severity of doxorubicin-induced myocardial damage. The prior 
administration of F3 (2-chloro) and F4 (4-chloro) (100, 200 mg/kg), showed 
significant reduction in doxorubicin -induced elevated CK-MB, LDH and troponin I 
serum marker enzymes. This reduction in the enzyme level confirms flavonoid I 2-
chloro and flavonoids II 4-chloro (100, 200 mg/kg), that is responsible for maintenance 
of normal structural and architectural integrity of cardiac myocytes, thereby restricting 
the leakage of these enzymes, which can be accounted for membrane stabilizing 
property48. 
LIVER FUNCTION TESTS 
This study shows the liver enzymes like AST, ALT and ALP enzyme activities 
are important measures of both early and late phases of cardiac injury. It is reported 
that serum AST, ALT and ALP were increased after Doxorubicin administration. ALP 
activity on endothelial cell surface is responsible, in part, for the conversion of 
adenosine nucleotides to adenosine, a potent vasodilator and anti-inflammatory 
mediator that can protect tissues from the ischemic damage that results from injury. 
This may account for the elevation of ALP in the Doxorubicin treated group, where 
tissue injury and inflammation are prominent. The evaluation of these enzymes 
together may be an indication of myocardial injury. In the preventive group, i.e. F3 (2-
chloro) and F4 (4-chloro) (100, 200 mg/kg) and doxorubicin, the AST, ALT and ALP 
enzyme levels were decreased to a level near to that of control group, suggesting that 
F3 (2-chloro) and F4 (4-chloro) (100, 200 mg/kg) may protect the myocardial tissue 
against Dox toxicity49. 
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BIOCHEMICAL ESTIMATION OF SERUM PARAMETERS 
LIPID PROFILE 
Lipid consist of triglycerides (neutral fat), total cholesterol, HDL and LDL and 
VLDL cholesterol. Cardiotoxicity is also related with the altered lipid metabolism. 
Increase in cholesterol level was observed due to the decrease in HDL, since HDL is 
known to be involved in the transport of cholesterol from tissues to the liver for its 
catabolism. The cholesterol-lowering drugs could significantly reduce the risk of heart 
attack by lowering the cholesterol level but they do not react with the free radical 
produced by doxorubicin, and hence they failed to exert protective action against 
doxorubicin-induced cardiotoxicity87.  
Increase in triglycerides might be due to a decrease in the activity of lipoprotein 
lipase, resulting in decreased uptake of triglycerides from the circulation and decreased 
level of phospholipid was observed due to enhanced membrane degradation in 
doxorubicin-treated rats. These changes in lipid levels might be due to enhanced lipid 
biosynthesis by cardiac cyclic adenosine monophosphate. Pre-treatment with F3 (2-
chloro) and F4 (4-chloro) (100, 200 mg/kg) decreases the concentration of total 
cholesterol, TGs, VLDL and increases the concentration of HDL in the heart of 
doxorubicin-induced rats. Studies have shown that high levels of LDL cholesterol have 
a positive correlation with myocardial infarction, whereas high levels of HDL 
cholesterol have a negative correlation with myocardial infarction. The level of these 
enzymes is decreased in the serum of F3 (2-chloro) and F4 (4-chloro) (100, 200 mg/kg) 
pre-treated doxorubicin-induced animal due to the protective action of F3 (2-chloro) 
and F4 (4-chloro) (100, 200 mg/kg) which reduces the damage of myocardium and 
prevents the leakage of marker enzymes in the serum87. 
BIOCHEMICAL ESTIMATION OF HEART TISSUE PARAMETERS 
TOTAL PTOTEIN & MDA 
The mechanism of cardiotoxicity induced by doxorubicin is not clearly known 
from the present study, although large body of evidence indicates toward the formation 
of oxygen free radicals, which can damage cells by lipid peroxidation. In doxorubicin 
treated animals, we found significant increase in heart tissue malondialdehyde (MDA) 
levels suggesting increased lipid peroxidation. Cardiac tissue damage may be due to 
increased oxidative stress and depletion of antioxidants. In our study, doxorubicin 
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treated rats showed increase in heart tissue malondialdehyde (MDA) and total protein 
levels which confirms the oxidative stress and cardiac damage. F3 (2-chloro) and F4 
(4-chloro) (100, 200 mg/kg) prevented the Dox-induced changes in malondialdehyde 
(MDA) and total protein suggests the protective effect of these flavonoids78. 
 
ENZYMATIC ANTIOXIDANTS 
The doxorubicin treated rats showed decrease in levels the of enzymatic 
antioxidants like superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), 
reduced glutathione (GSSH), and non-enzymatic antioxidant GSH which confirms the 
oxidative stress and cardiac damage. The treatment of F3 (2-chloro) and F4 (4-chloro) 
(100, 200 mg/kg) prevented the Dox-induced changes in MDA and enzyme levels. 
Significant increase in the GSH, SOD and CAT activity and decrease in lipid 
peroxidation in heart tissue of F3 (2-chloro) and F4 (4-chloro) (100, 200 mg/kg) and 
doxorubicin treated groups was found that, study suggests the protective effect of 
flavonoids. It is commonly accepted that SOD protects against the free radical injury 
by converting O2- radical to H2O2 and prevent the formation of OH radicals through 
O2- driven Fenton reaction and the H2O2 can be removed by catalase. Administration 
of these flavonoids improved the antioxidant status and thereby preventing the damage 
to the heart, mainly because of the antioxidant sparing action78. 
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CONCLUSION 
 
Flavonoids are polyphenolic compounds having certain biological activities 
such as anti-inflammatory, anticancer, anti-viral, anti-thrombotic, anti-ischaemic and 
also cardioprotective activity, because of its wide variety of pharmacological actions 
and it can be synthesized and their structural identification was done by UV, IR, and 
Mass spectroscopic techniques. Therefore, identification and characterization of 
flavonoid moieties is a promising approach against myocardial infarction.  
Based in silico do0cking, molinspiration-drug likeness properties and ADMET 
checking five flavonoids were selected and synthesized. The angiotensin converting 
enzyme was isolated from the sheep lungs and the synthesized compounds were tested 
for in vitro inhibitory property of angiotensin converting enzyme. The in vivo 
cardioprotective activity were tested by inducing myocardial infarction using 
doxorubicin.  
Based on the in vitro angiotensin converting enzyme inhibitory assay, it was 
found that two of the synthesized flavonoids (2-chloro and 4-chloro) possess 
cardioprotective activity. These 2 flavonoids showed maximum inhibition at lower 
concentration. In vivo studies were done for two flavonoids (2-chloro and 4- chloro) 
by doxorubicin induced myocardial infarction in rats. They possess a protection 
against doxorubicin induced myocardial infarction in rats. The present study suggests 
the protection offered by antioxidant enzymes and lipid peroxidation and reactive 
oxygen species and also, mitochondrial dysfunction.  
The concluded results indicated that administration of doxorubicin leads to 
myocardial infarction moreover, from the biochemical and histopathological 
parameters, the present investigation suggest that 2-chloro and 4-chloro synthesized 
flavonoids can protect the doxorubicin induced myocardial infarction in rats. More 
advanced cohort studies are thus necessary to understand the absolute risk of 
doxorubicin and their mechanism for myocardial infarction and further extensive 
preclinical research of the synthesized flavonoids on the molecular and cellular targets 
have to be established before these chemical moieties are taken for clinical trials. 
48 
 
REFERENCES 
1. Greene RJ, Harris ND. Pathology and therapeutics for pharmacists. 
2008;(3):58-61,258-59. 
2. Kumar V, Babu V, Nagarajan K, Machawal L, Bajaj U. Protective effects of 
Centella asiatica against isoproterenol-induced myocardial infarction in rats. 
Journal of Phytopharmacology. 2015;4(2):80-6  
3. Zafari AM, Abdon MH. Myocardial infarction. The heart organisation Med-
scape. 2017. 
4. Goel A, Goel D, Yadav Y, Gupta SK. Correlation of 2D-Echocardiography 
Findings in Young Patients of Myocardial Infarction with Prevalence of Risk 
Factors. IAIM Journal. 2016;3(10): 221-27. 
5. Channamma G. Age and Gender distribution in patients with acute 
Myocardial Infarction. Medica innovatica. 2016;5(1):29-31. 
6. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F et al. 
Mechanisms of myocardial infarction in women without angiographically 
obstructive coronary artery disease.African journal of primary health 
2011;124:1414-25. 
7. Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre 
AG et al. Frequency of provoked coronary arterial spasm in 1089 consecutive 
patients undergoing coronary arteriography. Circulation. 1982;65:1299-1306. 
8. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. 
Long-term follow-up of patients with mild coronary artery disease and 
endothelial dysfunction. Circulation. 2000;101:948-54. 
9. Kristian R. Third universal definition of myocardial infarction. European 
Heart Journal. 2012;33:2551-67. 
10. Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. 
Biomedical reports. 2015;3:743-48 
11. Arbustini K. Plaque erosion is a major substrate for coronary thrombosis in 
acute myocardial infarction. European heart journal. 1999;82(3):269-72 
12. Simpson PJ, Lucchesi BR. Role of free radicals and myocardial ischemia and 
reperfusion injury. European Heart Journal. 1987;110(1)13-30  
13. Kumar S, Pandey AK. Chemistry and biological activity of flavonoids. The 
scientific world Journal. 2013;1-17. 
49 
 
14. Sun NM. Isorhamnetin Protects against Doxorubicin-Induced Cardiotoxicity 
In Vivo and In Vitro. 2013;8(5): e64526, doi:10.1371/journal.pone.0064526 
15. Kelly EH, Anthony RT, Dennis JB. Flavonoid antioxidants chemistry, 
metabolism and structure-activity relationships. Journal of Nutritional 
Biochemistry. 2002;13(10):572–584. 
16. Tromp J. Structural aspects of antioxidant activity of flavonoids. Free Radical 
Biology and Medicine. 1996;20(3):331–42 
17. Organization for Economic Co-operation and Development, Test No. 420: 
Fixed Dose Procedure, OECD Guidelines for the Testing of Chemicals, 
Section 4: Health Effects. OECD Publishing, Paris: 2002 
18. Mishra A, Kumar S, Bhargava A, Sharma B, Pandey AK. Studies on in vitro 
antioxidant and anti-staphylococcal activities of some important medicinal 
plants. Cellular and Molecular Biology. 2011;57(1):16–25 
19. Pan MH, Lai CS, Tho C. Anti-inflammatory activity of natural dietary 
flavonoids. Food and Function. 2010;1(1):15–31 
20. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a 
review of the epidemiological evidence. Nutrition and Cancer.1992;18(1):1–
29. 
21. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids. The 
Scientific World Journal. 2013:1-16. 
22. Raina GS. Significant emergent role of flavonoids as valuable nutraceuticals. 
International Journal of Pharmacotherapy.2013;3(2):44-51 
23. Tapas AR, Sakarkar DM, Kakde RB. Flavonoids as neutraceuticals: Tropical 
journal of pharmaceutical research. 2008;7(3):1089-99  
24. Krishna DR, Sripal RM and Chaluvadi MR. Bioflavonoids classification, 
pharmacological, biochemical effects and therapeutic potential. Indian Journal 
of pharmacology. 2001;13:2-6.  
25. Meng XY, Zhang HX, Cul M. Molecular docking: A powerful approach for 
structure-based drug discovery. 2011;7(2):146-57. 
26. Sliwoski G, Sandeepkumar K, Meiler J, Edward W. Application of 
computational methods for the design of BACE-inhibitors: validation of in 
silico modelling. Computational methods of drug discovery. 2013;66(1):334-
95. 
50 
 
27. Alexander H, Rolf H. Modern methods of drug discovery. Spinger. 2009: 207. 
28. Goodford PJ. A computational procedure for determining energetically 
favourable binding sites on biologically important macromolecules. Journal of 
Medicinal Chemistry. 1985;28(7):849–57. 
29. Kastenholz MA, Pastor M, Cruciani G, Haaksma EE, Fox T. A new 
computational tool to design selective ligands. Journal of Medicinal 
Chemistry. 2000;43(16):3033–44. 
30. Levitt DG, Banaszak LJ. A computer graphics method for identifying and 
displaying protein cavities and their surrounding amino acids. Journal of 
Molecular Graph. 1992; 10(4):229-34. 
31. Laskowski RA. A program for visualizing molecular surfaces, cavities, and 
intermolecular interactions. Journal of Molecular Graph.1995; 13(5):323–30. 
32. Glaser F, Morris RJ, Najmanovich RJ, Laskowski RA, Thornton JM. A 
method for localizing ligand binding pockets in protein structures. Proteins. 
2006; 62(2):479–88. 
33. Brady GP, Stouten PF. Fast prediction and visualization of protein binding 
pockets with pass. Journal Computer Aided Molecular Design. 
2000;14(4):383–401. 
34. Mezei M. A new method for mapping macromolecular topography. Journal of 
Molecular Graph Model. 2003;21(5):463–72 
35. Reddy S, Priyadarshini PS, Praveen KP, Pradeep HN, Narahari SG. Virtual 
screening in drug discovery - A computational perspective. Current Protein 
and Peptide Science. 20078:329-51. 
36. Mukesh B, Rakesh K. Molecular docking a review. International Journal of 
Research in Ayurveda and Pharmacy. 2011;2(6):1746-51. 
37. Patil S. Design, synthesis and biological activities of new substituted 3-
benzoyl flavone. 2013;4(2):1-10. 
38. Rangaraju A and Veerabhadra AR. A review on molecular docking – Novel 
tool in drug design and analysis. Journal of Harmonized Research in 
Pharmacy. 2013;2(4):215-21. 
39. Zhang HX, Xuan YM, Mihaly M, Meng C. Molecular docking: a powerful 
approach for structure-based drug discovery. 2011;7(2):146–57. 
51 
 
40. Ranjini. HS, Padmanabha U, Thomas JM. Angiotensin Converting Enzyme 
(ACE): Inhibition of Sheep Kidney and Lung ACE In vitro by Rauwolfia 
serpentina and Allium sativum. Scholars Journal of Applied Medical Sciences. 
2015;3(5B):1936-40. 
41. Swamy V. Cardioprotective effect of curcumin against doxorubicin -induced 
myocardial toxicity in albino rats.2012;44(1):73-7. 
42. Hafeefz A, Askari H, Khan N, Akram M, Hanif S, Urooj N. Molecular 
modelling of plant flavonoids as angiotensin converting enzyme inhibitors: A 
docking study. World Journal of Pharmaceutical Sciences. 2004;499-506. 
43. Shafaei A, Khan MSS, Aisha AFA, Majid AMSA, Hamdan MR, Mordi MN et 
al. Flavonoids-Rich Orthosiphon stamineus Extract as New Candidate for 
Angiotensin I-Converting Enzyme Inhibition: A Molecular Docking Study. 
Molecules. 2016;21:1-16. 
44. Kshatriya RB, Shaikh YI, Nazeruddin GM. Synthesis of flavone by different 
methods. Oriental Journal of Chemistry. 2013;29(4):1475-87. 
45. Patil S. Design, synthesis and biological activities of new substituted 3-
benzoyl flavone. 2013;4(2):1-10. 
46. Tang l. A novel approach to the synthesis of 6-amino-7-hydroxy-
flavone.2004;(9):842-48. 
47. Douglas T. The novel angiotensin-converting enzyme homolog ACE 2 is 
selectively expressed by adult Leydig cells of the testis. Endocrinology, 
2004;145(10):4703-11. 
48. Sabeur M. Characterization of angiotensin-converting enzyme in canine testis. 
Reproduction. 2001;122(1):139-46. 
49. Dargie H. Expert consensus document on angiotensin converting enzyme 
inhibitors in cardiovascular disease. European Heart Journal. 
2004;25(16):1454-70. 
50. Krishna DR, Sripal RM, Chaluvadi MR. Bioflavonoids classification, 
pharmacological, biochemical effects and therapeutic potential. Indian Journal 
of Pharmacology. 2001;13:2-16. 
51. Meng XY, Zhang HX, Mezei M, and Cui M. Molecular Docking: A powerful 
approach for structure-based drug discovery. 2011;7(2):146–57. 
52 
 
52. Ferreira LG, Santos RND, Oliva G, Adriano D. Andricopulo. Molecular 
Docking and Structure-Based Drug Design Strategies. Journal of 
Computational Chemistry. 2015;6(4):1-12. 
53. Fischer E. Einfluss der configuration auf die wirkung derenzyme. Ber. Dt. 
Chem. Ges. 1894;27:2985-93. 
54. Gregory AP, Dagmar R. X-ray crystallography in the service of structure-
based drug design.  Drug design-structure and ligand-based approaches. 
2010:17-29. 
55. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and 
validation of a genetic algorithm for flexible docking. Journal of Molecular 
Biology. 1997;2:727-48.  
56. Morris GM, Huey R, Lindstrom W. AutoDock4 and AutoDockTools4: 
Automated docking with selective receptor flexibility. Journal of 
Computational Chemistry. 2009;30:2785–91. 
57. Kumar R, Kumar A, Sharma R, Baruwa A. Pharmacological review on natural 
ACE inhibitors. 2010;2(2):273-93. 
58. Chen T, Wang ZH, Hsu CC, Lin HH, Chen JH. Taiwanese and Japanese yam 
extracts attenuate doxorubicin-induced cardiotoxicity in mice.2016;1-9.  
59. Hafeez S. Molecular modeling of plant flavonoids as angiotensin converting 
enzyme.2014;2(5):499-506. 
60. Shafaei A, Khan MSS, Aisha AFA, Majid AMSA, Hamdan MR, Mordi MN et 
al. Flavonoids-Rich Orthosiphon stamineus Extract as New Candidate for 
Angiotensin Converting Enzyme Inhibition. 2016;2-16. 
61. Khathriya. Synthesis of Flavone Skeleton by Different Methods. Oriental 
Journal of Chemistry. 2013;29(4):1475-87. 
62. Tang A. A novel approach to the synthesis of 6-amino-7-hydroxy flavone. 
Molecules. 2004;9:848-49. 
63. Huang WH, Chien PY, Yang CH, Lee AR. Novel Synthesis of Flavonoids of 
Scutellaria baicalensis. 2003;51(3):339-40. 
64. Chen CT, Wang ZH, Hsu CC, Lin HH, Chen JH. Taiwanese and Japanese 
yam Dioscorea spp. extracts attenuate doxorubicin-induced cardiotoxicity in 
mice. 2016:1-9. 
65. Nagathan BCS, Vishwanathswamy A, Pramod C, Gadad, Thippeswamy A. 
Cardioprotective effect of Vedic Guard against doxorubicin-induced 
53 
 
cardiotoxicity in rats: A biochemical, electrocardiographic, and 
histopathological study. Pharmacognosy Magazine. 2013;9:(34):176-82. 
66. Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD et al. High 
sensitivity cardiac troponin I at presentation in patients with suspected acute 
coronary syndrome.  2015;8(12):123-38. 
67. Molinspiration Cheminformatics. Available online: 
http://www.molinspiration.com [Accessed on 9 May 2015]. 
68. Jarrahpour G. Osiris and Molinspiration (POM) together as a successful 
support in drug design: Antibacterial activity and biopharmaceutical 
characterization of some azo Schiff bases. 2012;21:1984–90. 
69. Spitzer T. One concept, three implementations of 3D pharmacophore-based 
virtual screening: Distinct coverage of chemical search space. J. Chem. Inf. 
Model. 2010;50: 1241–47. 
70. Kelly EH, Anthony RT, Dennis JB. Flavonoid antioxidants: chemistry, 
metabolism and structure-activity relationships. Journal of Nutritional 
Biochemistry. 2002;13(10):572–84. 
71. Prasad A, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes DR. Significance 
of periprocedural myonecrosis on outcomes following percutaneous coronary 
intervention. 2008;1:10-9. 
72. Patil N, Chavan V, Karnik ND. Antioxidant status in patients with acute 
myocardial infarction. Indian Journal of Clinical Biochemistry. 
2007;22(1):45-51. 
73. Mitry MA, John G. Edwards Doxorubicin induced heart failure: Phenotype 
and molecular mechanisms.2016;(10):17-24. 
74. Witt, Trendelendurg. Clinical biotech. Journal of clinical 
chemistry.1982;(20):235. 
75. Klin. chem. Kiln biochem.1972;(1):1820. 
76. Adams et al., Diagnosis of perioperative myocardial infarction with 
measurements of cardiac troponin i. England journal of medicine. 1994; 
330:670. 
77. Thefeld et al.,;Dtsch. Med Wschr. 1994;99:343. 
78. Thefeld et al.,;Dtsch. Med Wschr. 1974;99:343. 
79. Jacobs, Arch D., Biochem, Biophy.1960;88:250-255 
54 
 
80. Williams et al., high density lipoprotein and coronary risk factor, 
lancet.1979;1:72 
81. Virendra KD, Tanwara OP, Sahaa R, Marellaa A, Mumtaz A, Mymoona A. 
Prediction and comparison of drug likeliness properties of primaquine and its 
structural analogues using in-silico ADME and toxicity prediction tools. 
Journal of Advanced.2014;5(3):172-82. 
82. Ranjini. HS, Padmanabha U, Thomas JM. Angiotensin Converting Enzyme 
(ACE): Inhibition of Sheep Kidney and Lung ACE In vitro by Rauwolfia 
serpentina and Allium sativum. Scholars Journal of Applied Medical Sciences. 
2015;3(5B):1936-40. 
83. Swamy AHMV, Wangikar U, Koti BC, Thippeswamy AHM, Ronad PM, 
Manjula DV. Cardioprotective effect of ascorbic acid on doxorubicin-induced 
myocardial toxicity in rats. Indian Journal of Pharmacology. 2011;43(5):507-
11. 
84. Ayaz SA, Bhandari K, Pillai K. Influence of DL and lipoic acid and Vitamin E 
against doxorubicin induced biochemical and histological changes in cardiac 
tissue of rat. Indian Journal of Pharmacology.2005;37:294-9. 
85. Davey MS, Atlee CW. Inotropic and cardioprotective effect of Terminalia 
paniculata roth bark extract in doxorubicin- induced cardiotoxicity in rats. 
2011;2(3):869-75 
86. Lowry OH, Rosenbourgh NJ, Farr AL, Randall RJ. Protein measurements 
with Folin phenol reagent. J Biol Chem. 1951;193:265-75. 
87. Hodyson BV, Foot JMP, Croft KD, Puddy IB, Mori TA, Beilin LJ. In vitro 
antioxidant activity of black and green tea, effects on lipoprotein oxidation in 
human serum. J Sci Food Agric. 1999;79:561-66. 
88. Sinha AK. Colorimetric assay of catalase. Anal Biochem. 1972;47:389-94. 
89. Paglia DE, Valentine WN. Studies on the quantitative and qualitative 
characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 
1967;70:158-9. 
90. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of 
superoxide dismutase. Indian J Biochem Biophys. 1984;2:130-2.  
91. Racker E. Enzymatic synthesis and breakdown of desoxyribose phosphate. J 
Biol Chem. 1952;196:347-65. 
55 
 
92. Ellman GL. Tissue sulphydryl groups. Arch Biochem Biophys.1959;2:70-7. 
93. Abirami M, Kanagavalli U. Cardioprotective effect of grapeseed 
proanthocyanidin on doxorubicin induced myocardial injury in rats. 
International journal of pharmacy and life sciences. 2013;4(1): 2288-93 
94. Virendra KD, Tanwara OP, Sahaa R, Marellaa A, Mumtaz A, Mymoona. A 
Prediction and comparison of drug likeliness properties of primaquine and its 
structural analogues using in-silico ADME and toxicity prediction tools. 
Journal of Advanced Bioinformatics Applications and 
Research.2014;5(3):172-82. 
 
 
 

 
